document incorporate reference portion definitive proxy statement registrant annual meeting shareholder file day conclusion registrant fiscal year end december securities exchange commission pursuant regulation security exchange act amend incorporate reference iii annual report extent describe thereinbristolmyer squibb company index december item business acquisition divestiture license arrangement product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation human capital management resource foreign operation bristol myers squibb website item risk factor item unresolved staff comment item cybersecurity item property item legal proceeding item safety disclosure information executive officer item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive income consolidate balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item information item disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit index end item business general bristolmyers squibb company company bms incorporate law state delaware august bristol myers company successor new york business start bristolmyer company change bristolmyer squibb company result merger operate segment engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis expect plan acquisition karuna rayzebio announce fourth quarter mirati turn point acquisition continue position lead biopharmaceutical company expand target oncology portfolio therapeutic area include neuroscience principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology hematology immunology cardiovascular neuroscience priority continue renew diversify portfolio advance early mid latestage pipeline execute disciplined business development remain committed strengthen balance sheet return capital shareholder discussion strategy initiative refer item management discussion analysis financial condition result operationsstrategy compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency significant manufacturing operation puerto rico switzerland ireland netherlands revenue come product follow therapeutic class hematology oncology cardiovascular immunology percentage revenue significant regioncountry follow year end december dollar millions united states international othera total revenue revenue include royalty alliancerelate revenue product sell bmss regional commercial organization refer summary abbreviate term end definition capitalize term document acquisition divestiture license arrangement acquisition divestiture license arrangement allow focus resource growth opportunity drive great longterm value significant business development activity include acquisition mirati complete january plan acquisition karuna rayzebio announce december iii global strategic collaboration agreement systimmune announce december additional information relate acquisition divestiture license arrangement refer item management discussion analysis financial condition result operationsacquisition divestiture license arrangement item financial statement supplementary datanote alliance item financial statement supplementary datanote acquisition divestiture license arrangement product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologics chimeric antigen receptor cart cell therapie small molecule drug typically administer orally form tablet capsule drug delivery mechanism biologic typically administer patient injection intravenous infusion cart therapy administer patient intravenous infusion summary significant product include approve indication information alliance arrangement certain product refer alliance item financial statement supplementary datanote alliance inline product eliquis eliquis apixaban oral factor inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy opdivo opdivo nivolumab biological product fully human monoclonal antibody bind nkt cell approve anticancer indication include bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc gastric esophageal cancer ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent orencia orencia abatacept biological product fusion protein indicate adult patient moderate severe active psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate pomalystimnovid pomalystimnovid pomalidomide small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy yervoy yervoy ipilimumab biological product ctla immune checkpoint inhibitor yervoy monoclonal antibody treatment patient unresectable metastatic melanoma opdivoyervoy regiman approve multiple market treatment nsclc melanoma mpm rcc crc esophageal cancer sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml new product portfolio reblozyl reblozyl luspaterceptaamt biological product erythroid maturation agent indicate treatment anemia adult patient transfusion dependent nontransfusion dependent beta thalassemia require regular red blood cell transfusion adult patient low intermediaterisk mds ring sideroblast require red blood cell transfusion iii adult patient previous erythropoiesis stimulate agent use esanave low intermediaterisk mds require regular red blood cell transfusion regardless ring sideroblast status opdualag opdualag nivolumab relatlimabrmbw combination nivolumab block antibody relatlimab lag blocking antibody indicate treatment adult pediatric patient year age old unresectable metastatic melanoma abecma abecma idecabtagene vicleucel bcma genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticyclic adp ribose hydrolase monoclonal antibody zeposia zeposia ozanimod oral immunomodulatory drug treat relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult treat moderately severely active adult breyanzi breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma specify highgrade bcell lymphoma primary mediastinal large bcell lymphoma grade camzyos camzyos mavacamten cardiac myosin inhibitor indicate treatment adult symptomatic obstructive hcm improve functional capacity symptom sotyktu sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicate treatment adult moderatetosevere plaque psoriasis candidate systemic therapy phototherapy onureg onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy inrebic inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary post polycythemia vera postessential thrombocythemia augtyro augtyro repotrectinib kinase inhibitor indicate treatment adult patient locally advanced metastatic rospositive nsclc recent loe product revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revlimid receive approval indication hematological malignancy include lymphoma mds abraxane abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity provide rdp period time approval new drug regulatory agency rely innovators data approve competitor generic copy develop country provide certain nonpatent incentive development medicine example japan certain country rdp exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic medicine business refer competition specific aspect law govern market patent protection rdp pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovator company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application receive certain period regulatory exclusivity nda bla compound designate orphan drug receive seven year exclusivity orphan drug indication period fda generally approve application drug product orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity type application file nda bla affect rdp exclusivity right discuss chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid unenforceable infringe generic product allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right medicine approve nda receive type rdp innovative chemical pharmaceutical product entitle year rdp fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear rdp period pharmaceutical drug product contain active ingredient previously approve nda approve example new formulation new route administration drug new indication basis new clinical study receive year rdp formulation route administration indication market chemical product include eliquis pomalyst sprycel zeposia onureg inrebic camzyos sotyktu augtyro repotrectinib biologic product include cart cell therapy product healthcare legislation enact create approval pathway biosimilar version innovative biological product fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar version file year approval innovator product qualify innovative biological product receive year rdp mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda market biologic product include opdivo orencia yervoy reblozyl abecma opdualag breyanzi increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file october november subject rdp regime year innovator receive community authorization medicinal product generic company file maa product health authority maa approved generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment contrast patent list regulatory authority generic version pharmaceutical product approve rdp expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property rdp addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan patents pharmaceutical product enforceable extend compensate patent term lose regulatory review process medicine new chemical entity generally afford year rdp approve indication dosage generic copy receive regulatory approval rdp patent expiration general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right rdp exclusivity currently estimate occur japan estimate minimum market exclusivity date sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside japan generally estimate minimum market exclusivity date table pertain end rdp com patent expiration respective product ptr grant situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration rdp estimate minimum market exclusivity date product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limit estimate estimate minimum market exclusivity date eup japan abecma idecabtagene vicleucel abraxane paclitaxela augtyro repotrectinibb breyanzi lisocabtagene maraleucelc camzyos mavacamtend eliquis apixabane inrebic fedratinibf onureg azacitidineg opdivo nivolumab opdualag nivolumab relatlimabrmbwh orencia abatacepti pomalystimnovid pomalidomidej reblozyl luspaterceptaamtk revlimid lenalidomidel sotyktu deucravacitinibm sprycel dasatinibn yervoy ipilimumab zeposia ozanimodo product footnote information currently market product country region indicate abraxane generics enter market japan estimate minimum market exclusivity date june aware generic enter market december augtyro ptr application pende grant estimate patent expiry breyanzi ptr application pende grant estimate patent expiry camzyo ptr application pende grant estimate patent expiry spc application pende grant estimate patent expiry eliquis patent list fda orange book composition matter patent claim apixaban specifically expire formulation patent expiring challenge numerous generic company bms partner pfizer settle number generic company settle generic company continue litigate remain generic company remain generic company august district court district delaware decide challenge eliquis patent valid infringe remain generic company remain generic company appeal september court appeal federal circuit uphold decision respect patent term previously execute settlement agreement settle generic company permit date launch settle generic company patent april subject additional challenge apixaban composition matter patent relate spc expire generic challenge composition matter patent relate spc jurisdiction trial take place schedule place certain european country legal proceeding pende generic manufacturer begin market generic version eliquis certain country seek market generic version eliquis country prior expiration date apixaban patent relate spc refer item financial statement supplementary datanote legal proceeding contingency information estimate minimum market exclusivity date base rdp exclusivity onureg estimate minimum market exclusivity date base seven year orphan drug exclusivity formulation patent cover onureg expire japan generic company challenge formulation patent list fda orange book litigation ongoing formulation patent cover onureg pende opposition proceeding epo opposition division find formulation patent invalid decision appeal refer item financial statement supplementary datanote legal proceeding contingency information opdualag ptr application pende grant estimate patent expiry spc application pende grant estimate patent expiry bms aware orencia biosimilar market japan formulation additional patent expire pomalyst currently expect generic entry prior quarter europe estimate minimum market exclusivity date august base rdp exclusivity japan estimate minimum market exclusivity date base method use patent reblozyl europe estimate minimum market exclusivity date base rdp exclusivity ptr application method treatment patent pende grant estimate patent expiry spc application method treatment patent pende grant estimate patent expiry revlimid settlement natco pharma ltd natco partners affiliates natco grant volumelimite license sell generic lenalidomide commence march certain generic company grant volumelimite license sell generic lenalidomide begin confidential date march volumelimite license date provide natco natco certain generic begin market generic lenalidomide product pursuant volumelimite license addition natco generic company grant license sell generic lenalidomide volume limitation begin january japan generics enter market sotyktu ptr application pende grant estimate patent expiry spc application pende grant estimate patent expiry japan ptr application pende grant estimate patent expiry sprycel bms enter settlement agreement apotex inc certain company patent cover certain polymorphic form dasatinib generic company launch generic dasatinib anda product september early certain circumstance lawsuit file bm pende generic company contain paragraph certification seek approval dasatinib product epos opposition division uphold validity patent direct use dasatinib treat cml expire settlement agreement certain generic launch generic dasatinib approve indication japan composition matter patent extend treatment nonimatinibresistant cml generic dasatinib product launch approve indication refer item financial statement supplementary datanote legal proceeding contingency information zeposia ptr application pende grant estimate patent expiry estimate minimum market exclusivity date country base france germany italy spain research development critical longterm competitiveness concentrate effort follow disease area significant unmet medical need oncology include lung bladder renal gastric esophageal head neck colorectal melanoma tumor type hematology cell therapy include multiple myeloma lymphoma chronic lymphocytic leukemia immunology include relapse multiple sclerosis psoriasis lupus inflammatory bowel disease cardiovascular include cardiomyopathy heart failure thrombotic disorder fibrotic disease specifically lung liver neuroscience condition include neuroinflammation neurodegeneration neuropsychiatry continue analyze selectively pursue promising lead area pipeline include potential medicine modality include small chemically manufacture molecule large protein moleculesalso know biologicsand degrader tcell nkcell engager millamolecule antibody drug conjugate cellular therapy gene therapy addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase phase iii clinical study design specifically support application regulatory approval particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant program program include investigational compound phases iii development initial indication market product development additional indication formulation substantial component program strategy include expand portfolio market product hematology immunology cardiovascular agent secondline therapy new indication drug development time consume expensive risky process target identification major market approval typically take fourteen year drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately small molecule enter phase development fail achieve regulatory approval small molecule enter phase development failure rate approximately approximately phase iii small molecule fail achieve approval biologic failure rate approximately phase development approximately phase development approximately phase iii expense include cost discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support market product proportionate allocation enterprisewide cost acquire iprd include upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval expense billion billion billion acquire iprd expense million million billion manage program product portfolio basis invest resource stage early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense drug discovery development work take place network stateoftheart facility worldwide continue investment exist site expansion manufacturing capability example expand lawrenceville new jersey site open facility cambridge massachusetts opening facility san diego california plan addition support continue investment cell therapy portfolio continue expand manufacturing capability construction new stateoftheart cell therapy manufacturing facility devens massachusetts complete leiden netherlands libertyville illinois currently ongoe supplement internal drug discovery development program acquisition alliance collaborative agreement help bring new molecular agent capability platform pipeline broad earlytomid stage pipeline unique asset clinical development pipeline build couple internal research development program distribute research development model focus identify support development disruptive innovative therapy outside company broad network external partnership management continue emphasize leadership innovation productivity quality strategy success activity list clinical study approve indication market product relate therapeutic area february list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound hematology phase phase phase iii approve indication investigational compound additional indication additional indication abecma alnuctamabmezigdomide breyanzi abecma multiple myeloma relapsedrefractory multiple myeloma chronic lymphocytic newly diagnose multiple multiple myeloma antisirp leukemia myeloma suboptimal multiple myeloma hematologic malignancy relapsedrefractory follicular response postasct breyanzi lymphoma reblozyl bcl ldd large bcell lymphoma relapsedrefractory marginal ntd mds associated anemia lymphoma zone lymphoma associated anemia large bcell lymphoma bcma nke relapsedrefractory mantle cell empliciti pomalystimnovid relapsedrefractory multiple myeloma lymphoma relapsedrefractory multiple myeloma bet inhibitor bms reblozyl empliciti revlimid relapsedrefractory nonhodgkin athalassemia relapsedrefractory multiple myeloma lymphoma investigational compound idhifa cdgspt adc alnuctamab relapsedrefractory acute myeloid leukemia acute myeloid leukemia mre yla los me arefractory multiple inrebic nke investigational compound iberdomide myelofibrosis egy eid leukemia bet inhibitor bms multiple myeloma onureg hematologic malignancy lcl doy efibrosis heo mto alo ing wel mpo eion acute myeloid leukemia tual target bcmaxgprcd car relapsedrefractory non diagnose multiple myeloma opdivo hodgkin lymphoma mezigdomide advanced hodgkin lymphoma relapsedrefractory multiple myeloma multiple myeloma pomalystimnovid golcadomide multiple myeloma multiple myeloma diffuse large bcell lymphoma relapsedrefractory multiple myeloma gprcd car aid relate kaposi sarcoma relapsedrefractory multiple myeloma hivnegative kaposi sarcoma reblozyl transfusiondependent betathalassemia mds previously treat esa transfusiondependent mdsassociated anemia revlimid multiple myeloma mantle cell lymphoma mds multiple myeloma previously treat follicular lymphoma relapsedrefractory adult tcell leukemialymphoma sprycel cml pediatric refractory cml oncology phase phase phase iii approve indication investigational compound additional indication additional indication abraxane anticcr augtyro repotrectinib krazati breast solid tumor ntrk pan tumor nsclc gastric antiilt krazati colorectal cancer locally advanced metastatic nsclc solid tumor nsclc opdivo metastatic breast cancer ldd colorectal cancer periadjuvant muscle invasive nsclc metastatic castration nivolumab relatlimab urothelial carcinoma pancreatic resistant prostate cancer stage nsclc adjuvant hcc unresectable pancreatic dgk inhibitor hepatocellular carcinoma periadjuvant nsclc stage augtyro repotrectinib solid tumor iiia adjuvant nsclc ros nsclc helios celmod opdivo yervoy krazati solid tumor inu mcl invasive urothelial advanced nsclc krasgc mutation jnk inhibitor investigational compounds hcc opdivo solid tumor antictla probody msihigh crc metastatic melanoma mage tcer therapeutic stage iii unresectable nsclc gastric solid tumor lung cancer opdualag esophageal squamous cell carcinoma nme colorectal cancer adjuvant melanoma esophageal prostate cancer antifucosyl adjuvant melanoma prmt inhibitor relapsedrefractory small cell adjuvant bladder solid tumor lung cancer adjuvant esophagealgastroesophageal gop fli itn nuh hmi boi irt tso ar iti mag prd eej vsu ota uhn set yim tre eala teo dii solid tumor nonsmall cell lung cancer melanoma previously treat gastric cancer japan china tigit bispecific bet inhibitor bms subcutaneous nivolumab previously treat metastatic head neck gastric cancer solid tumor rhuph multiindication previously treat metastatic melanoma farletuzumabecteribulin rcc previously treat metastatic msihigh crc ovarian cancer previously treat metastatic nonsquamous nsclc nonsmall cell lung cancer previously treat metastatic squamous nsclc previously treat metastatic urothelial cancer previously treat esophageal cancer neoadjuvant nsclc opdivo cabozantinib metastatic rcc opdivo yervoy metastatic melanoma mesothelioma nsclc rcc previously treat metastatic msihigh crc previously treat hcc esophageal gastric opdualag melanoma yervoy adjuvant melanoma metastatic melanoma immunology phase phase phase iii approve indication investigational compound additional indication additional indication orencia anticd sotyktu sotyktu active polyarticular jia autoimmune disease alopecia areata psoriatic arthritis early rheumatoid arthritis nex discoid lupus erythematosus systemic lupus erythematosus jia intravenous severe refractory systemic lupus sjgren syndrome jia subcutaneous erythematosus zeposia psoriatic arthritis ilcd crohns disease auto injector autoimmune disease investigational compound intravenous nme afimetoran subcutaneous autoimmune disease systemic lupus erythematosus acute graft versus host disease pkc inhibitor tyk inhibitor bms investigational compound sotyktu autoimmune disease moderatetosevere psoriasis cendakimab moderatetosevere psoriasis eosinophilic esophagitis zeposia eosinophilic gastroenteritis relapse multiple sclerosis lpa antagonist moderatetosevere ulcerative colitis idiopathic pulmonary fibrosis progressive pulmonary fibrosis obexelimab iggrelate disease cardiovascular phase phase phase iii approve indication investigational compound additional indication additional indication camzyos fxia inhibitor camzyos camzyos symptomatic obstructive hypertrophic thrombotic disorder heart failure preserve nonobstructive hypertrophic cardiomyopathy ejection fraction hfpef cardiomyopathy eliquis stroke prevention atrial fibrillation venous thromboembolism prevention orthopedic surgery investigational compound investigational compound venous thromboembolism treatment danicamtiv milvexian genetic dilate cardiomyopathy acute coronary syndrome myk atrial fibrillation obstructive hypertrophic secondary stroke prevention ssp cardiomyopathy heart failure preserve ejection fraction hfpef neuroscience phase investigational compound antimtbrtau alzheimer disease nex multiple sclerosis eifb activator neuroscience faahmgll dual inhibitor neuroscience tyk inhibitor bms neuroinflammation disorder note pipeline exclude clinical collaboration development partnership abecma seventy bio farletuzumab ecteribulin eisai rhuph halozyme magea tcer immatic milvexian janssen pharmaceuticals inc johnson johnson company opdivo yervoy opdualag japan ono pkc inhibitor exscientia reblozyl merck shp inhibitor bridgebio pharma tigit bispecific agenus obexelimab zenas biopharma japan south korea taiwan singapore australia trials explore combination partnerrun study japan follow registrational study readout anticipate oncology immunology asset tumor trial asset disease trial krazati nsclc tps krystal cendakimab eoe imp krazati crc krystal sotyktu psa poetykpsa krazati mutate nsclc krystal sotyktu psa poetykpsa yellowstone opdivo adjuvant hcc cmdx zeposia crohn disease induction yellowstone opdivo periadjuvant miuc zeposia crohn disease induction hematology asset disease trial asset disease trial breyanzi relapsedrefractory mzl transcend camzyos nhcm odysseyhcm reblozyl associate anemia independence confirmatory trial alliance enter alliance arrangement party development commercialization specific product drug candidate therapeutic area focus alliance structure codevelopment cocommercialization license joint venture arrangement arrangement include upfront payment option payment develop commercialize specific asset technology payment developmental regulatory salesbase performance milestone royalty cost reimbursement profit sharing equity investment provision alliance arrangement lessen investment risk compound lead revenue generating product reduce profitability market product profit share royalty payment actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern arrangement typically provide termination bms cause notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure bms terminate cause bms right terminate cause exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation loss cash flow cause loss right material financial condition liquidity alliance agreement structure terminate specific date product patent expiration date expiry date profit sharing payment typically expiration date royalty payment typically cease loss market exclusivity include patent expiration refer item financial statement supplementary datanote alliance information significant alliance agreement alliance agreement marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor specialty pharmacy less extent directly distributor retailer hospital clinic government agency revlimid pomalyst distribute primarily contract pharmacy lenalidomide risk evaluation mitigation strategy rem revlimid pomalyst rem program respectively proprietary mandatory riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use camzyos available camzyos rem program product distribution limit rem certify pharmacy enrol pharmacy dispense patient authorize receive camzyos program vary country depend country design riskmanagement program product sell hospital retail pharmacy refer item financial statement supplementary datanote revenue gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire june subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion competition market compete generally broadbase highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer therapy continue evolve rapid pace product particularly opdivo operate highly competitive marketplace addition compete market share product approve indication lung cancer melanoma face increase competition exist compete product receive fda approval additional indication new agent receive fda approval enter market furthermore therapy combine different product product exist chemotherapy target therapy treatment investigate potential expand approval anticipate product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer certain country include regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent challenge generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing patient support program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize collaboration appropriate improve access care supportive service vulnerable patient collaboration demonstration project important factor pricing medicine depend government regulation subject increase international domestic effort government implement strengthen measure regulate pharmaceutical market access product pricing payment require provide discount purchase pharmaceutical product federal state healthcare program federal government official legislator continue face intense pressure public manage perceive high cost pharmaceutical respond pursue legislation inflation reduction act ira rules claim potentially reduce cost drug federal government stakeholder discussion ira refer item businessgovernment regulation require comply state law seek additional transparency cost prescription drug monitor effort state seek additional rebate limit state spend drug light budget pressure international federal state legislative regulatory development create new constraint ability set price andor impact market access certain area discussion pricing pressure risk refer item businessgovernment regulation item risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin growth consolidation mcos pbm optum uhc cvs health cvs express script esi major factor healthcare marketplace pbms control nearly prescription market own payer unitedhealthcare aetna cigna respectively mco pbms consolidate few large entity enhance purchasing strength share voice market half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physicians physician organization pbms party support formulary management contracting mco successfully compete formulary position mcos pbms demonstrate product offer medical benefit cost advantage compare form care exclusion product formulary lead sharply reduce usage patient population high outofpocket cost patient consequently pharmaceutical company compete aggressively product include formulary new product introduce compete product market product later develop competitor possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy usually provide rebate pbm important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco pbm formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject direct government control point care government serve primary payer result product face restrict access high pocket expense patient pricing pressure public private payer subject assessment comparative value effectiveness exist standard care government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact mandate price cut rebate scheme method cost control countries example government regulate price new product launch direct price control international price comparison andor reference pricing current standard care price reevaluated restrict life medicine markets germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product year elapse new medicine available patient market additionally country outside regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spending clawback trend accelerate recent year example germany reform pricing reimbursement system restrain pharmaceutical spending reduce free pricing period introduce new costcontainment measure medicine base value assessment result use combination medicine japanese government continue impose price cut outside normal repricing cycle year introduce new value assessment requirement medicine cut price existence price differential market particularly neighboring country different national pricing reimbursement condition lead potential parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency rebate drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market regulatory review process resource intensive undertake fda pharmaceutical company improvement efficiency process significant impact bring new therapy patient quickly fda employ tool facilitate development certain drug expedite certain application include fast track designation breakthrough therapy designation priority review accelerate approval incentive orphan drug develop rare disease example recent year fda oncology center excellence oce establish project test novel approach efficient regulatory review oncology drug realtime oncology review pilot program assessment aid assessment aid pilot program fda approve opdivo give cycle platinumdoublet chemotherapy march firstline treatment adult patient resectable nsclc neoadjuvant set approval achieve month priority review pdufa date july develop framework concurrent review supplemental oncology application multiple approval authority oce initiate project orbis project orbi early approval australian therapeutic good administration tga health canada united kingdoms medicines healthcare product regulatory agency receive combination opdivo give cycle platinumdoublet chemotherapy fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse event use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain safety relate drug labeling change iii mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical study prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize knowingly offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement administration procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed law regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate medicaid drug rebate program mdrp pay rebate state medicaid program cover outpatient drug provide medicaid beneficiary rebate base pricing datum report regularly center medicare medicaid services cms participate health resource services administration program offer cover outpatient drug statutorily define covered entity program ceiling price price calculate base mdrpreported datum participate federal government program specify discount certain federal government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase recent year legislative policy proposal introduce low drug price example august president biden sign inflation reduction act ira law provide government set negotiate price select highcost medicare begin medicare drug begin year smallmolecule drug year biological product initial fda approval manufacturer pay rebate medicare drug price increase fast inflation begin medicare medicare drug iii medicare redesign replace current coverage gap discount program cgdp establish cap outofpocket limit cost medicare beneficiary begin manufacturer responsible cost cap cap reach august department health human service select eliquis medicine subject governmentset price begin possible product select future year thing accelerate revenue erosion prior expiry intellectual property protection effect reduce price reimbursement certain product significantly impact business consolidate result operation discussion legislation impact refer item management discussion analysis financial condition result operationsexecutive summary addition december biden administration release propose framework time propose drug price factor determine drug accessible public government exercise marchin right license party manufacture comment period proposal run february able predict final rule adopt line propose adopt government seek exercise marchin right product proposal relate calculation good price potential executive order focus drug pricing debate state level multiple state pursue government action ballot initiative address limit drug pricing reimbursement medicaid programs initiative include drug importation canada attempt use ira reference drug price state level statelevel proposal influence federal policy legislation give uncertainty surround adoption time potential legislative policy administrative change unable predict exact impact business enact change modify decrease access coverage reimbursement product impact rebate shift cost turn material impact business result operation activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material component supply require manufacturing product open market product purchase raw material component supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate potential risk associate raw material component supply inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network consist internal external resource manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical manufacturing process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval manage operate flexible manufacturing network minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologic cell therapy pharmaceutical manufacturing facility locate puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increase regulatory requirement example fda approve deven massachusetts commercial facility cart manufacturing june continue capital investment deven massachusetts manufacturing facility cell therapy product candidate market product include breyanzi abecma invest manufacturing network include facility bothell washington summit new jersey deven massachusetts leiden netherlands libertyville illinois use thirdparty manufacturer addition expect continue modification exist manufacturing network meet complex processing standard require grow portfolio particularly biologic cell therapy biologic manufacturing involve complex process traditional pharmaceutical operation regulatory requirement product involve technically sophisticated manufacturing process require specialized raw material example manufacture clinical commercial use sterile product biologic product cart product particularly complex involve highly specialized manufacturing technology result slight deviation point production process lead production failure recall order address production constraint cart cell therapy manufacturing continue partner party manufacturer expand supply vector invest new facility drug product manufacturing longerterm accelerate plan transition new vector technology dual source strategy addition manufacture site rely party manufacture supply portion active product ingredient drug substance necessary manufacture product include eliquis opdivo pomalystimnovid yervoy sprycel reblozyl abraxane zeposia camzyos sotyktu inrebic expand use thirdparty manufacturer drug product finish good manufacturing continue shift thirdparty manufacturer supply mature brand maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier reduce risk interruption manufacturing operation certain supply arrangement extend multiple year commit amount expect near longterm demand requirement subject change additional protection case step maintain approve backup source available need example capability manufacture opdivo drug product internally arrangement thirdparty manufacturer meet demand opdivo drug substance drug product connection acquisition divestiture license collaboration arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party intend continue enter arrangement agreement future addition liability arise failure supply product agreement arrangement agreement require invest facility manufacture nonstrategic product case divestiture distribution arrangement result additional regulatory filing obligation cause interruption manufacture strategic product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility maintenance planning manufacturing warehouse logistic distribution maintain record demonstrate quality integrity datum technical information production process control production process involves establish specification standard raw material component ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process raw material drug substance final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier help ensure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment occupational health safety sustainability group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statement supplementary datanote legal proceeding contingency human capital management resource believe employee world embody mission discover develop deliver innovative medicine help patient prevail disease unyielde focus patient define culture demographic december approximately employee country approximately employee locate exclude puerto rico locate outside supplement workforce contingent temporary worker certain specialized skilled service provide independent contractor average tenure employee approximately seven year people strategy bms global community compassionate purposedriven professional live vision transform patient live science people strategy design foster inclusive engage work experience attract develop retain talented workforce reflect diverse culture background experience patient community world strive inspire career experience enable people realize aspiration nurture healthy energize flexible workplace foster collaboration innovation cultivate inclusive environment diverse workforce feel sense belong value unique perspective excel pursuit science innovation patient prioritize investment enterprisewide comprehensive cohesive strategy program policy initiative describe accelerate personal development collaboration service patient believe investment competitive advantage recruit develop retain future workforce drive innovation people practice unrelenting push breakthrough science global inclusion diversity inclusion diversity strengthen foundation bms achieve breakthrough help serve unmet evolve need patient community world compel longstanding commitment elevate inclusion diversity health equity drive equitable advancement outcomes global strategy lead value inclusion core value regionally locally relevant strengthen human connection bring work day discover develop deliver medicine help patient prevail disease thrive culture belong cultivate encourage inclusive engagement innovation encourage employee worldacross diverse culture background experiencesto authentic self work speak think boldly create energized environment collaboration codesign bold idea solution lead improved patient outcome patient community colleague industry deserve global strategy enable people business resource group pbrg operationalize organization design maintain pbrg chapter worldwide member network learn skill participate learn development event contribute global strategy tangible way pbrg sponsor member executive leadership team lead fulltime dedicated leader report directly member executive leadership team pbrg include black organization leadership development bms network woman cultivate leadership innovation multigenerational belong disability advancement workplace network pride alliance organization latino achievement pan asian network veteran community network pbrg membership grow unique member chapter country october approximately bms employee member pbrg global strategy include fiveyear inclusion diversity aspirational goal health equity commitment launch increase diversity clinical trial globally improve efficacy safety medicine leverage strengthen diversity workforce well understand unique need preference patient community iii collaborate global community improve education access ensure partner provide culturally competent appropriate care drive economic empowerment community serve invest diverse business enhance innovation agility supply chain advance aspirational goal continue advance strategy drive equitable access outcome patient communitie globally career growth development bms enterprise learn vision build workforce capable accelerate future growth power mindset continuous learn bms champion learn development people important asset recognize potential achieve career aspiration drive business success aspire create future ready workforce develop critical skill need tackle organization press strategic priority ondemand openenrollment learning journey customize nominationbase experience aim unlock personal potential exceptional learning experience extensive library resource available multiple language employee cover wide range specialized subject employee enrol professional manager leadership development program tuition reimbursement offer globally eligible employee initiation desire development participate accredit highereducational program support pbrg affiliation tour duty stretch assignment opportunity challenge people encourage ownership skill development career advancement culture employee engagement workforce compose exceptional individual critical mission discover develop deliver innovative medicine help patient prevail disease workforce focus patient embody value integrity passion inclusion innovation accountability urgency employee fundamental mission want ensure workforce culture thrive routinely check engagement employee global employee pulse survey confidential quarterly pulse survey conduct employee provide feedback employee satisfaction cover variety topic company culture value execution strategy diversity inclusion individual development survey result review executive officer board director analyze area progress opportunity company level function level individual manager use survey result implement action activity intend increase wellbee employee believe employee engagement initiative competitive pay benefit program career growth development opportunity help increase employee satisfaction tenure reduce voluntary turnover give criticality engage motivated workforce select employee engagement goal incorporate annual bonus program metric executive compensation wellbee provide highly competitive compensation wellbee offering enable workforce deliver business strategy compensation include market competitive base salary annual incentive recognize reward company performance individual result long term equity incentive focus employee longterm value creation offer salesbase incentive special allowance peertopeer individual recognition executive substantial proportion pay variable atrisk base financial operational result deliver form equity support alignment executive compensation program creation longterm value shareholder wellbee committed prioritize wellbee workforce live life well strategy encourage physical emotional work life financial wellbee employee ensure global consistency local relevance competitiveness live life well establish framework global set standard concentrate key area inclusive benefit mental health family care people disabilitie caregiver gender preventive care framework enhance employee experience remove barrier access improve health outcome live life well ground science emphasize flexibility inclusion ensure employee support good meet individual need right moment signature live life well program include physical emotional work life financial program employee health safety commit protect workforce community patient ensure continue supply lifesave medicine goal ensure employee contractor visitor site work conduct visit safely achieve rigorous application control risk mitigation measure define health safety management system incident near miss investigate root cause lesson learn effectively share avoid recurrence comprehensive assurance program place objectively assess effectiveness adherence standard corrective preventive action track closure provide comprehensive inhouse occupational health service primary objective ensure workrelate illness disease identify early worker health protect range medical assessment include fitnessforduty preplacement reproductive health travel health wellness check conduct employee disability return illness support rigorous legally compliant accommodation process appropriate foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristol myers squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act document available secs website wwwsecgov information relate corporate governance bristol myers squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director board include board committee committee charter transaction bristol myers squibb security director executive officer available website usour company leadership investor caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsshareholder service caption addition information sustainability program available website ussustainability caption forego information website content convenience information contain connected website deem incorporate reference file sec incorporate reference certain information part definitive proxy statement annual meeting shareholder proxy statement sec allow disclose important information refer manner refer information proxy statement available website investorsfinancial reportingsec filing caption day end fiscal year item risk factor risk uncertainty describe significantly negatively affect business operation financial condition operate result include component financial result cash flow prospect reputation credit rating future cause trading price common stock decline significantly additional risk uncertainty presently know risk currently consider immaterial impair business operation financial condition operate result cash flow follow discussion risk factor contain forwardlooke statement discuss item management discussion analysis financial condition result operationsspecial note forwardlooke statement product industry operational risk increase pricing pressure restriction abroad continue negatively affect revenue profit margin product continue subject increase pressure portfolio pharmaceutical market access pricing control require rebate discount region world result low price low reimbursement rate small population payer reimburse expect market access constraint pricing control discount restriction acute public private payer continue aggressive step control expenditure future revenue profit margin negatively affect include result change law regulation relate pricing reimbursement pharmaceutical product include potential penalty increase price rate inflation new discount fund redesign medicare benefit government negotiationsprice control change determination good price establish maximum allow pricereimbursement rate change relate federal healthcare program modify federal antikickback statute discount safe harbor ira include number provision intend low cost drug cover medicare medicare limit medicare beneficiary outofpocket spending medicare benefit costcutte measure federal healthcare program medicare medicaid mcos institutional governmental purchaser iii grant additional authority governmental agency manage drug utilization negotiate drug price include implementation regulation issue federal government authorize state private party develop implement program import certain prescription drug canada sell american rescue plan act eliminate medicaid prescription drug rebate cap start january expand utilization drug pricing program program competition relate placement applicable commercial medicare formularie change federal pharmaceutical coverage reimbursement policy practice vii increase scrutiny drug manufacturer include additional review bms celgene house oversight reform committee viii reimbursement delay government price erosion mechanism europe country result deflation pharmaceutical product pricing increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary collection delay failure pay governmentfunde public hospital outside xii development technology andor industry practice impact reimbursement policy practice thirdparty payer xiii inhibit market access real perceive difference value proposition product compare compete product particular ira effect reduce price reimbursement certain product significantly impact business ira department health human service effectively set price certain singlesource drug biologic reimburse medicare generally government price apply year small molecule drug year biological product follow fda approval cap statutory ceiling price likely represent significant discount average price wholesaler direct purchaser august department health human service select eliquis medicine subject governmentset price begin medicare price setting process begin february conclude august september cms publish price applicable drug medicare program begin january possible product select future year thing accelerate revenue erosion prior expiry intellectual property protection ira require drug manufacturer provide rebate medicare medicine certain circumstance benefit redesign replace cgdp new manufacturer discount program begin january ira percent cgdp discount replace percent manufacturer discount medicare beneficiary meet deductible incur pocket drug cost threshold percent discount beneficiary incur pocket drug cost threshold new benefit redesign manufacturer fail comply ira subject penalty include civil monetary penalty significant ira continue meaningfully impact business strategy pharmaceutical industry impact ira business pharmaceutical industry include implication competitor product select price setting remain uncertain state level multiple state pursue government action ballot initiative address limit drug pricing reimbursement medicaid program initiative include attempt use ira reference drug price state level statelevel proposal influence federal policy legislation give uncertainty surround adoption time potential legislative policy administrative change unable predict impact business enact change modify decrease access coverage reimbursement product impact rebate shift cost turn material impact business result operation additionally manufacturer find knowingly intentionally overcharge program cover entity subject significant monetary penalty course past year celgene receive inquiry human resource services administration limited distribution network revlimid pomalyst thalomid compliance program broad integration strategy alignment distribution model post acquisition celgene corporation announce beginning march recognize designate program contract pharmacy location program hospital lack entityowne pharmacy believe comply continue comply applicable legal requirement additional legal legislative change respect program cause update approach significant change sale pricing practice regard distribution drug program material change payer channel mix adverse effect revenue profitability addition require pay penalty applicable regulation adverse effect revenue profitability additional information pricing pressure constraint refer item businesspricing price constraint market access experience difficulty delay development commercialization new product ability replace revenue product lose patent protection directly dependent ability successfully commercialize new product timely manner common pharmaceutical industry bms expect sale key brand product like eliquis revlimid pomalyst sprycel abraxane decline loss market exclusivity product consequently future success highly dependent pipeline new product high rate failure inherent research development process new drug result high risk fund invest research program generate financial return compound product appear promise development fail reach market expect optimal timeframe experience setback continue addition product extension additional indication approve furthermore product indication approve fdas accelerate approval program contingent verification description clinical benefit confirmatory study study successful develop commercialize new compound product involve inherent risk uncertainty include efficacy safety concern finding superior safety efficacy compete product delay deny regulatory approval include result difficulty enrol patient complete clinical trial timely manner iii delay challenge produce product commercial scale excessive cost manufacture product failure enter implement optimal alliance development andor commercialization new product change regulatory approval process policy cause delay denial new product approval preclusion commercialization intellectual property issue dispute party vii failure certain market obtain reimbursement commensurate level innovation clinical benefit present product viii change clinical preference change industry standard law regulation competitor innovation render new product enhancement exist product obsolete unable predict change law regulatory policy occur affect business particularly pipeline new product regulatory approval delay especially common product expect rem program require fda address significant riskbenefit issue expect certain future key product distribute primarily rem program inability bring product market significant delay expect regulatory approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural man disaster act sabotage negatively impact product development cycle provide assurance product development approve launch product launch commercially successful public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key latestage product candidate delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure shortterm longterm material adverse effect business result operation cash flow financial condition prospect assurance key product candidate prove safe effective safe effective compete product approve product commercially successful approve indication lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain maintain patent intellectual property right limitation use loss right result rapid loss sale affect product material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty example eliquis generic challenge composition matter patent relate spc jurisdiction trial take place schedule place certain european country legal proceeding pende generic manufacturer begin market generic version eliquis certain country seek market generic version eliquis country prior expiration date applicable patent relate spc furthermore manufacturer innovative drug generic drug manufacturer able design product own license patent compete result alternative technology absent relevant patent protection product datum exclusivity period expire generic alternative version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject validity enforceability infringement challenge patent litigation postgrant review patent office proceeding confident strength intellectual property right possible generic drug company successfully challenge right launch generic version drug prior expiration intellectual property right example follow certain adverse judicial decision netherland generic manufacturer begin market generic version eliquis netherlands seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe addition order avoid uncertainty expense litigation reason decide enter settlement generic manufacturer permit generic market entry prior expiration intellectual property right example result patent settlement generic entry revlimid united kingdom begin january european country february similarly follow patent settlement certain company grant volumelimite license sell generic lenalidomide commence march case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation addition country allow manufacturer manufacture sell generic product negatively impact protection afford company lowerprice generic biosimilar bms biologic product compete biologic negatively impact volume price addition congress fda take step promote development approval generic drug biosimilar biologic include provide generic biosimilar developer private right action obtain sufficient quantity drug sample reference product manufacturer order conduct testing necessary obtain approval generic biosimilar product addition december biden administration release propose framework time propose drug price factor determine drug accessible public government exercise marchin right license party manufacture comment period proposal run february able predict final rule adopt line propose adopt government seek exercise marchin right product assurance particular product enjoy market exclusivity time period appear estimate disclose form assume provide financial guidance face intense competition manufacturer expect increase market penetration lowerprice generic product future growth bms dependent market access uptake expansion market brand new product introduction new indication product extension copromotional activity alliance partner competition keen lose exclusivity market brand lowerpriced generic product increasingly penetrate market generic challenge product arise time patent prevent emergence generic competition product country patent protection significantly weak political social pressure push legislation measure promote use generic biosimilar product additional information item risk factorswe lose market exclusivity product early expect addition face competition new product enter market particularly new product lower price superior efficacy benefit safety risk profile actual perceive iii technological advantage product convenient use well insurance coverage reimbursement level effective marketing program andor differentiate factor hard product compete predict accuracy timing impact introduction competitive product treat disease condition like treat product product candidate business combination competitor major thirdparty payer increase competition product unable compete successfully competitor product marketplace material negative impact revenue earning experience difficulty delay disruption supply chain manufacture distribution sale product product supply relate patient access future negatively impact difficulty delay disruption manufacture distribution sale product difficulty delay disruption include product seizure recall force closing manufacture plant failure failure vendor supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure supplier include sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation labor dispute shortage business interruption disruption supply chain continuity include market force recent stress global logistic natural disaster global disease outbreak pandemic include covid act war terrorism unforeseeable unavoidable event materially impact facility critical supplier addition manufacturing process novel cellbase therapy cart cell therapy evolve process complicate expensive approach take current future competitor ability source raw material supply manufacture cart cell therapy develop consistent reliable manufacturing process distribution network attractive cost good impact future anticipate revenue gross profit cart cell therapy furthermore face challenge source raw material supply clinical approve commercial manufacture logistical shipment delay factor control prevent delay delivery product candidate market product patient additionally require maintain complex chain identity custody respect patient material material enter move manufacturing process result slight deviation point production process cart cell therapy material cart cell therapy result loss product regulatory remedial action adversely affect future anticipate revenue andor profitability relate cart cell therapy regulatory intellectual property litigation tax legal compliance risk litigation claim infringement intellectual property adversely affect future revenue operate earning certain subsidiary future involve legal proceeding include patent litigation claim patent invalid unenforceable andor cover product generic drug manufacturer party seek damage andor injunctive relief compensate allege infringement patent commercial activity resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage andor injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product safety liability consumer protection commercial case iii anti bribery regulation foreign corrupt practice act bribery act include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant allege failure fulfill obligation supply contract government customer agreement relate business product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation viii environmental health safety sustainability matter include regulatory action response climate change tax liability result assessment tax authority subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company law regulation control regulate key aspect business include limited market access pricing control discount tax liability return payment iii import trade restriction intellectual property protection enforcement good practice guideline regulation accounting standard vii datum storage privacy particularly viii requirement report payment value transfer healthcare professional provide federal antikickback statute compliance antibribery anticorruption practice country addition healthcare industry highly regulate subject frequent substantial change including result new judicial governmental decision example congress pass food drug omnibus reform act december give fda additional authority require confirmatory trial underway time approval offer additional enforcement mechanism sponsor complete study diligence predict future federal state legislative administrative change relate healthcare reform affect business additional information refer item businessgovernment regulation item businesspricing price constraint market access adverse outcome legal matter negatively affect business similarly legislative regulatory environment privacy datum protection continuously evolve subject significant attention regulator private party globally regulator impose new datum privacy security requirement include new great monetary fine penalty privacy violation jurisdiction operate pass continue propose datum privacy legislation regulation failure comply current future law result significant penalty reputational harm material adverse effect business result operation expectation relate environmental social governance consideration relate reporting obligation expose company potential liability increase cost reputational harm adverse effect company business increase focus foreign federal state local regulatory legislative body investor stakeholder environmental policy relate climate change regulate greenhouse gas emission carbon taxis emission trading scheme sustainability human right diversity inclusion equity matter disclosure forego ambiguous inconsistent dynamic conflicting expect experience increase restriction compliance cost legal cost expense relate new change legal regulatory requirement compliance legal regulatory requirement require devote substantial time attention matter addition subject penalty potential litigation law regulation interpret apply manner inconsistent practice time time establish publicly announce environmental social governance goal commitments implementation environmental social governance goal initiative involve risk uncertainty require investment depend thirdparty performance datum outside control addition stakeholder disagree company environmental social governance goal target objective meet perceive meet stakeholder disagree environmental social governance goal target objective risk negative stakeholder reaction include proxy advisory service damage brand reputation reduce demand product negative impact business operation change tax regulation negatively impact earning subject income taxis country globally change tax law regulation occur significant judgment require determine company tax liability company tax return periodically examine tax authority face continue face audit challenge apply tax law regulation ultimate resolution tax matter result payment great amount accrue negative impact provision income taxis addition future earning negatively impact change tax legislation include change tax rate tax base limit phasingout eliminate deduction tax credit increase tax certain excess income intellectual property revise tax law interpretation domestic foreign jurisdiction change rule earning repatriation change tax law country notably july october oecdg inclusive framework agree general rule redefine jurisdictional taxation right global minimum tax december member state voted unanimously adopt directive implement pillar global minimum tax rule give member state december implement directive national legislation certain jurisdiction operate oecdg inclusive framework enact legislation adopt subset rule effective january remain rule effective january rule associate legislative change significantly impact tax provision result operation implementation pillar currently expect increase effective tax rate exclude specify item approximately failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing human resource finance datum business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization produce reliable result iii perform timely manner maintain confidentiality proprietary information incur significant cyberattack business disruption subject government order mandate require priority government set aside preexist commercial order vii dispute arise respect ownership right technology develop partner viii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party satisfactorily meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act eus general data protection regulation similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence product labeling change market product result negative impact revenue profit margin pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration additional clinical trial headto head study adverse event report follow use product long period time study identify biomarker objective characteristic indicate particular response product therapy conduct obtain marketing approval product regulatory change standard safety efficacy labeling result product label change measure reduce product market acceptance result decline revenue additional information new study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution mcos scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact operating result new information add product label affect risk benefit profile lead potential voluntary mandatory recall withdrawal decline revenue product liability claim additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue addition safety efficacy concern raise party product class product concern implicate entire class turn adverse impact availability commercial viability product product class illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug product divert authorized market risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand divert product prevalence counterfeit medicine industrywide issue variety factor include adoption ecommerce increase covid pandemic greatly enhance consumer ability obtain prescription medical treatment internet lieu traditional brick mortar pharmacy internet expose patient great risk prefer vehicle dangerous counterfeit offer scam anonymity afford counterfeiter theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use social medium cause brand damage information leakage rise liability include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill cause significant volatility stock price disclosure nonpublic companysensitive information workforce intentional unintentional external medium channel lead loss trade secret intellectual property company commercially sensitive information information technology cybersecurity risk dependent information technology system face risk cybersecurity incident disrupt business result theft proprietary confidential information rely extensively information technology system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor party vendor assist conduct business face continue face risk incident cyber attack cyber intrusion cloud internet phishing attempt ransomware form malware computer viruse email attachment extortion scam effort maintain security integrity information technology system system proprietary confidential personal information reside transmit subject risk cybersecurity incident disruption assurance security effort measure thirdparty vendor prevent breakdown incident thirdparty vendor system adversely affect business strategy result operation financial condition cybersecurity risk continue develop include result threat actor increasingly target employee supply chain geopolitical tension lead increase sabotage espionage cyber attack cyberthreat landscape evolve attack grow frequency sophistication intensity nature attack risk remain undetected period time significant breakdown invasion corruption destruction interruption critical information technology system leak theft proprietary confidential personal information negatively impact operation assurance continue effort prevent breakdown incident thirdparty provider system database adversely affect business certain circumstance incident detect require disclosure government authority andor regulator require notification impact individual incident result material financial legal business reputational harm strategic business development employee attraction retention risk depend key product revenue cash flow earning derive majority revenue earning key product expect revlimid eliquis opdivo represent significant percentage revenue earning cash flow year reduction revenue product loss market exclusivity factor adversely impact earning cash flow additional information item risk factorswe lose market exclusivity product early expect major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity supply disruption manufacturing operation party supplier significant advancement compete product incur adverse impact business financial condition result operation trading price stock addition product distribute wholesaler wholesaler encounter financial difficulty unable timely collect amount wholesaler owe negatively impact result operation thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture diabete business include transfer certain future royalty right pertain amylin onglyza farxiga product sale outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period example royalty relate keytruda decrease january expect terminate december royalty relate tecentriq expect terminate december addition royalty divest diabetes business specifically amylin farxiga onglyza terminate december failure execute business strategy identify effectively manage acquisition divestiture alliance joint venture portfolio action adversely impact growth profitability future result addition business asset acquire future underperform able successfully integrate exist business occurrence number unexpected factor prevent substantially delay consummation anticipate acquisition divestiture merger strategy focus deliver innovative transformational medicine patient focus set disease area support future revenue growth maintain adequate pipeline acquire inlicense number asset expect continue support pipeline compound product obtain licensing acquisition competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable consistently maintain adequate pipeline internal program transaction party unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact additionally future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy result cost saving avoidance increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii tax consideration acquire debt equity security consideration business development activity connection joint venture acquisition value security fluctuate depreciate value control company acquire security connection collaborative arrangement result limited ability determine management operational decision internal control compliance policy result additional financial reputational risk successful separate underperform nonstrategic asset gain loss divestiture lose operating income asset affect earning divestiture result continued financial exposure divest business guarantee financial arrangement continue supply service arrangement potential litigation follow transaction arrangement nonperformance result obligation impose material adverse effect competitive position cash flow result operation financial condition reputation incur asset impairment charge related acquisition divestiture reduce earning value allocate certain asset substantially impair number factor control new revise accounting standard rule interpretation result change recognition income expense materially adversely affect financial result execution implementation acquisition divestiture alliance joint venture portfolio action successful adversely impact financial condition cash flow result operation substantial debt incur finance cash portion celgene myokardia mirati acquisition intend incur connection karuna rayzebio acquisition assurance able expand business development capacity commit reduce debt pursue strategic transaction opportunity future require obtain additional equity debt financing result increase leverage andor downgrade credit rating failure attract retain highly qualified workforce affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management workforce include people expertise clinical governmental regulation commercialization connection acquisition integrate corporate culture maintain employee morale face increase competition limit pool qualified individual numerous pharmaceutical biotechnology company university government entity research institution company seek enter healthcare space company industry sure able retain quality talent cost materially increase market liquidity credit risk significant indebtedness negative consequence acquisition celgene myokardia mirati increase debt result additional interest expense intend incur debt finance future acquisition include karuna rayzebio acquisition reduce financial flexibility continue capital investment develop new product declare future dividend example follow announcement recent acquisition standard poor downgrade bmss long termcredit rating stable longterm credit outlook adverse change global economic political condition adversely affect operation profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside global economic downturn create amplify variety risk business negatively affect growth addition uncertainty credit capital market impact growth strategy revenue earning cash flow expose risk strengthen dollar global inflation include operating cost significantly increase result rise inflation rate wage increase factor adversely affect revenue profitability exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union particular exit occur january create uncertainty affect business operation impact research commercial general business operation include approval supply product require change legal entity structure additionally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war pandemic epidemic covid pandemic affect demand product drive low patient start visit expect future pandemic similar effect addition experience significant manufacturing supply issue covid possible experience issue response future pandemic instance experience scarcity certain raw material component result influx pandemic relate vaccine order receive priority treatment vendor furthermore future epidemic pandemic create material staffing shortage manufacture site disrupt supply product possible experience supply chain interruption result quarantine shelterinplace governmental order policy travel restriction airline cargo capacity route reduction experience delay initiation enrollment patient clinical trial consequence future pandemic able fully mitigate delay negatively impact time pipeline development program expect future revenue andor cash flow prolong clinical trial delay potentially significant negative effect business particularly new competitive product enter market clinical trial result competitor product affect value proposition product delay difficulty clinical development potentially lead material impairment intangible asset include billion intangible asset december predict reasonably estimate impact potential longterm change healthcare industry global economic political event include future pandemic example potential shift payer channel mix change patient coverage current economic crisis able reliably estimate impact result operation give highly variable uncertain situation possible change healthcare system impose additional burden clinical trial increase cost sponsor clinical trial lead additional delay difficulty complete clinical trial experience additional pricing pressure andor increase governmental regulation global economic condition event war pandemic create additional risk impact supplier vendor outsource partner alliance partner party rely research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional services example thirdparty provider suffer limited solvency global economic condition negatively impact operating model business similarly global event ukraine russia conflict increase volatility financial market foreign currency exchange interest rate face potential negative consequence stem future pandemic global event include limited increase cyber threat partner cyber attack outage possible global economic political event include future pandemic exacerbate risk describe guarantee pay dividend repurchase stock declaration time dividend fall discretion board board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market reduce number share repurchase share repurchase program adversely affect stock price ira impose excise tax net repurchase share december imposition excise tax repurchase share increase cost make repurchase cause board reduce number share repurchase pursuant share repurchase program amend bylaw designate court chancery state delaware sole exclusive forum certain lawsuit stockholder limit stockholder ability obtain judicial forum find favorable lawsuit costly stockholder bring lawsuit effect discourage lawsuit amend bylaw provide consent write selection alternative forum court chancery state delaware full extent permit law sole exclusive forum derivative action proceeding bring behalf action assert claim breach fiduciary duty owe director officer employee stockholder creditor constituent iii action assert claim arise pursuant provision general corporation law state delaware amend restate certificate incorporation amend bylaw action assert claim director officer employee govern internal affair doctrine provide event court chancery state delaware lack jurisdiction action proceed sole exclusive forum action proceed state federal court state delaware bylaw provide person entity purchase acquire hold interest share capital stock deem notice consent forum selection provision court chancery state delaware court chancery jurisdiction state federal court state delaware full authority allow law issue antisuit injunction enforce forum selection clause preclude suit forum forum selection provision intend apply action bring securities act securities act amended exchange act section exchange act create exclusive federal jurisdiction suit bring enforce duty liability create exchange act rule regulation thereunder section security act create concurrent jurisdiction federal state court suit bring enforce duty liability create security act rules regulation thereunder accordingly forum selection provision amend bylaw relieve duty comply federal security law rule regulation thereunder stockholder deem waive compliance law rule regulation forum selection provision bylaw limit stockholder ability bring claim judicial forum find favorable dispute director officer employee discourage lawsuit respect claim stockholder deem waive compliance federal security law rule regulation thereunder addition stockholder bring claim court chancery state delaware face additional litigation cost pursue claim particularly reside near delaware believe risk court decline enforce forum selection provision contain amend bylaw low court find provision inapplicable unenforceable respect specify type action proceeding incur additional cost associate resolve action jurisdiction harm business operating result financial condition item unresolved staff comment item cybersecurity risk management strategy company manage cybersecurity risk overall enterprise risk management strategy oversee audit committee board company employ robust cybersecurity datum privacy program largely align national institute standard technology cybersecurity framework assess identify manage material risk cybersecurity threat constantly evolve cyber defense minimize impact cyber threat multipronged approach help safeguard asset datum particularly focus address emerge cybersecurity risk include human risk phishing attack remain common cause data breach thirdparty supply chain risk threat actor continue target supply chain compromise great number victim geopolitical risk tension conflict world accompany increase sabotage espionage cyber attack threat actor frequently target employee gain access information system comprehensive global human risk management program educate workforce threat face line defense include element address phishe malware datum handle device security cybersecurity education password security internet browsing defense physical threat employee expose datadriven cybersecurity awareness campaign training order pace industry standard evolve challenge innovative solution respect information security datum privacy cybersecurity risk organization additionally employ multilayere approach application cybersecurity technology help safeguard system network datum potential cybersecurity threat company acquire integration plan include appropriate workable timeline alignment information security datum privacy cybersecurity employee education support preparedness cybersecurity incident response plan cirp regularly update business need security landscape change event cybersecurity incident incident response team refer cirp exist management internal control disclosure process pursuant process designate personnel responsible assess severity incident associate threat contain resolve incident quickly possible manage damage company system network minimize impact company stakeholder analyze execute internal reporting obligation escalate information incident senior management appropriate perform postincident analysis program enhancement need perform periodic tabletop exercise annually test incident response procedure identify gap improvement opportunity exercise team preparedness engage party separately conduct cyber assessment recur basis assist containment remediation effort addition party technology analytic utilize identify potential vulnerability recognize party provide service company subject cybersecurity incident impact company manage thirdparty risk maintain thirdparty risk management program design assess security control party assessment methodology base risk rely datum access connectivity criticality service thirdparty offer note conduct tabletop exercise identify gap supply chain resilience implement improvement maintain relationship law enforcement government agency forensic investigator legal counsel inform cybersecurity datum privacy program december date file aware material cybersecurity incident impact company target cyber attack expect continue cybersecurity threat rapidly evolve sophistication prevalent industry face risk incident cyber attack cyber intrusion cloud internet phishing attempt ransomware form malware computer viruse email attachment extortion scam effort maintain security integrity information technology system system proprietary confidential personal information reside transmit subject risk cybersecurity incident disruption assurance security effort measure party vendor prevent breakdown incident thirdparty vendor system adversely affect business discussion risk item arisk factorsinformation technology cybersecurity riskswe dependent information technology system infrastructure face certain risk include cybersecurity incident datum leakage governance company cybersecurity datum privacy program implement overseen company chief information security officer ciso executive vice president chief digital technology officer senior management information security team responsible manage implement company cybersecurity datum privacy program year valuable business experience manage risk cybersecurity threat data privacy breach develop implement cybersecurity datum privacy policy procedure audit committee consist solely independent director oversee company overall enterprise risk assessment risk management policy guideline include risk relate cybersecurity matter audit committee review discuss management oversee company information security datum protection program particular audit committee receive periodic update ciso internal audit function member management significant cybersecurity datum privacy threat system potential impact company business financial result operation reputation risk management strategy include information governance security policy program program assessment plan improvement major legislative regulatory development materially impact company cybersecurity datum privacy policy program status information security initiative include appropriate threat assessment relate information technology risk update chair audit committee update board board receive similar cybersecurity update directly ciso member management annually need time time item property principal executive office locate route province line road princeton lease manufacturing administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer good operating condition provide adequate production capacity current project operation believe property subject material encumbrance easement restriction detract materially value impair use operation business information manufacturing property refer item businessmanufacture quality assurance significant manufacturing location geographic area follow december manufacturing united states europe total item legal proceeding information pertain legal proceeding find item financial statement supplementary datanote legal proceeding contingency incorporate reference item safety disclosure applicable information executive officer list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting shareholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year president head commercial christopher boerner phd president head international market chief executive officer executive vice president chief commercialization officer member leadership team executive vice president chief operating officer present chief executive officer giovanni caforio chief executive officer director company executive chairman board chairman board chief executive officer member leadership team present executive chairman board group vice president chief financial officer consumer consumer medicine johnson johnson david elkins worldwide vice president chief financial officer consumer product medical executive vice president chief financial officer development corporate function johnson johnson member leadership team chief financial officer celgene corporation present executive vice president chief financial officer cari gallman senior counsel legal executive vice president corporate affairs assistant general counsel oncology legal member leadership team vice president assistant general counsel worldwide oncology senior vice president chief compliance officer present executive vice president corporate affairs vice president investor relations abbvie inc head price commercial abbvie inc sharon greenlee head supply chain finance abbvie inc senior vice president corporate controller vice president controller finance operations abbvie inc present senior vice president corporate controller samit hirawat executive vice president head oncology development novartis executive vice president chief medical officer head development executive vice president chief medical officer global drug development member leadership team present executive vice president chief medical officer head development vice president immunooncology marketing lynelle hoch general manager ireland major market president cell therapy organization senior vice president global cell therapy franchise lead member leadership team present president cell therapy organization head oncology adam lenkowsky senior vice president general manager oncology immunology cardiovascular executive vice president chief commercialization officer senior vice president head major market member leadership team present executive vice president chief commercialization officer sandra leung executive vice president general counsel present executive vice president general counsel member leadership team greg meyers corporate vice president chief information officer motorola solutions executive vice president chief digital technology officer group chief information digital officer syngenta group member leadership team present executive vice president chief digital technology officer vice president inflammation immunology thematic center excellence unit robert plenge phd celgene corporation executive vice president chief research officer head research senior vice president immunology cardiovascular fibrosis thematic research center member leadership team senior vice president immunology cardiovascular fibrosis thematic research center head translational medicine senior vice president head discovery translational sciences present executive vice president chief research officer head research amanda poole vice president head human resource global product development supply executive vice president chief human resource officer vice president head bmscelgene integration member leadership team senior vice president head human resource commercialization senior vice president people strategy solution service present executive vice president chief human resource officer karin shanahan senior vice president chief operating officer global operation teva pharmaceutical executive vice president global product development supply senior vice president global biologics sterile operation merck member leadership team present executive vice president global product development supply item market registrant common equity relate stockholder matter issuer purchase equity securities bristol myers squibb common stock trade new york stock exchange symbol bmy holder common stock number record holder common stock january number record holder base actual number holder register book date base information provide shareowner service transfer agent include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company equity compensation plan information information require item contain proxy statement head item vote uponitem advisory vote approve compensation name executive officersequity compensation plan information information incorporate reference performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristol myers squibb peer group issuer purchase equity security follow table summarize surrender equity security month end december total number share approximate dollar value purchase share total number average price pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock follow authorization board subsequently approve additional authorization include recently february january december december billion billion billion billion respectively share repurchase authorization remain share repurchase capacity program billion december refer item financial statement supplementary datanote equity information share repurchase program represent approximately million share asr settle transfer treasury stock complete repurchase pursuant asr average repurchase price refer item financial statement supplementary datanote equity information item reserve item management discussion analysis financial condition result operation management discussion analysis financial condition result operation provide supplement read conjunction consolidate financial statement relate note include enhance understanding result operation financial condition cash flow comparison result omit incorporate reference year end december item management discussion analysis financial condition result operation file february executive summary bristolmyers squibb company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end definition capitalize term document receive approval initial additional indication follow market product major market japan expand geographical reach immunology hematology oncology cardiovascular disease approval opdivo treatment completely resect stage iib iic melanoma expand exist adjuvant treatment melanoma patient fda approval reblozyl firstline set treatment anemia previous erythropoiesis stimulate agent use adult patient low intermediaterisk mds require red blood cell transfusion regardless ring sideroblast status approval additional indication anemia associate nontransfusiondependent beta thalassemia iii approval japan opdivo combination chemotherapy neoadjuvant treatment patient resectable nsclc approval camzyos treatment symptomatic obstructive hcm approval breyanzi secondline treatment diffuse large bcell lymphoma approval sotyktu moderatetosevere plaque psoriasis vii approval augtyro repotrectinib generation tyrosine kinase inhibitor tki treatment adult patient locally advance metastatic ros nonsmall cell lung cancer nsclc continue expand commercial cart manufacturing network fda approval devens facility june january acquire mirati commercial stage target oncology company pipeline commercial clinical preclinical stage oncology medicine asset mirati acquisition obtain right krazati bestinclass inhibitor krasgc mutation approve fda secondline treatment patient nsclc mrtx potential firstinclass mtacooperative prmt inhibitor phase development addition fourth quarter enter definitive merger agreement acquire karuna rayzebio enter strategic collaboration systimmune karuna biopharmaceutical company drive discover develop deliver transformative medicine people live psychiatric neurological condition rayzebio clinicalstage radiopharmaceutical therapeutic company innovationleade position actiniumbase radiopharmaceutical therapeutic pipeline potentially firstinclass bestinclass drug development program refer item financial statement supplementary datanote acquisition divestiture license arrangement additional information goal collaboration systimmune codevelop cocommercialize blbd bispecific topoisomerase inhibitorbase antibody drug conjugate target egfr currently evaluate phase clinical trial metastatic unresectable nsclc refer item financial statement supplementary datum note alliance information company potential increase registrational portfolio potentially firstinclassbestinclass asset addition grow registrational portfolio company indication expansion opportunity horizon take lead increase depth company therapeutic area include oncology hematology immunology cardiovascular grow presence neuroscience financial highlight year end december dollar million share datum total revenue dilute earning share gaap nongaap revenues decrease primarily low revlimid sale drive previously disclose generic erosion increase patient receive free drug product revlimid less extent pomalyst bristol myers squibb patient assistance foundation partially offset high sale new product portfolio inline product primarily opdivo increase gaap eps primarily drive impact certain specify item include deferred income tax benefit relate nonus tax ruling low loss equity investment amortization intangible asset litigation settlement income partially offset low revenue product mix adjust specify item nongaap eps decrease primarily result low revenue product mix partially offset high royalty interest income lower weight average share outstanding nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation change nongaap financial measure refer nongaap financial measure economic market factor governmental action product continue subject increase pressure portfolio pharmaceutical market access pricing control discount change tax importation law restriction region world result low price low reimbursement rate small population payer reimburse negatively impact result operation include intangible asset impairment charge operate cash flow liquidity financial flexibility example august president biden sign ira law provide government negotiate price select highcost medicare begin drug begin year smallmolecule drug year biological product fda approval manufacturer pay rebate medicare drug price increase fast inflation begin iii medicare redesign replace current cgdp establishe cap outofpocket limit cost medicare beneficiary begin manufacturer responsible cost cap cap reach august department health human service select eliquis medicine subject governmentset price begin possible product select future year thing accelerate revenue erosion prior expiry intellectual property protection addition december biden administration release propose framework time propose drug price factor determine drug accessible public government exercise marchin right license party manufacture comment period proposal run february able predict final rule adopt line propose adopt government seek exercise marchin right product proposal relate calculation good price potential executive order focus drug pricing debate effect reduce price reimbursement certain product significantly impact business consolidate result operation additionally connection ira follow change tax law include minimum tax generally apply corporation adjust financial statement income begin nondeductible excise tax provision net stock repurchase apply repurchase begin continue evaluate impact ira legislation result operation possible change result material impact business result operation furthermore country expect change tax law update international tax treaty implement agreement oecd establish global minimum tax risk factor item include iitem risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin lose market exclusivity product early expect change tax regulation negatively impact earning significant product approval follow summary significant approval receive product date approval augtyro fda approval augtyro treatment adult patient locally advanced metastatic ros november repotrectinib positive nsclc fda approval opdivo adjuvant treatment adult pediatric patient year old opdivo october completely resect stage iib iic melanoma fda approval reblozyl treatment anemia previous erythropoiesis stimulate agent reblozyl august use esanave adult patient low intermediaterisk mds approval opdivo monotherapy adjuvant treatment adult adolescent year opdivo august age old stage iib iic melanoma undergone complete resection approval opdivo combination platinumbase chemotherapy neoadjuvant treatment opdivo june resectable nsclc high risk recurrence adult patient tumor cell pdl expression approval camzyos treatment symptomatic new york heart association class iiiii camzyos june obstructive hcm approval breyanzi treatment adult patient diffuse large bcell lymphoma high grade breyanzi cell lymphoma primary mediastinal large bcell lymphoma grade relapse month completion refractory firstline chemoimmunotherapy japan ministry health labour welfare approval opdivo plus chemotherapy neoadjuvant opdivo march treatment patient resectable nsclc approval sotyktu treatment adult moderatetosevere plaque psoriasis sotyktu march candidate systemic therapy approval reblozyl treatment adult patient anemia associate nontransfusion reblozyl march dependent beta thalassemia refer product pipeline development development market product latestage pipeline early strategy principal strategy combine resource scale capability large pharmaceutical company speed agility focus innovation typically find biotech industry priority continue renew diversify portfolio launch new medicine advance early mid latestage pipeline iii execute disciplined business development undergo period renewal strategy focus drive nearterm growth minimize impact transition period follow deliver growth late accelerate opportunity enhance productivity efficiency advance pipeline drive strong commercial execution business forward remain committed strategic business development maintain strong investment grade credit rating grow dividend reduce additional debt issue support recent transaction focus discover develop deliver transformational medicine patient face disease follow core therapeutic area oncology priority certain tumor type include diversification hematology opportunity expand leadership position multiple myeloma broaden portfolio leukemias lymphomas nonmalignant hematologic disease iii immunology priority strengthen presence dermatology rheumatology gastrointestinal disorder establish new standard care pulmonology rapidly advance cell therapy immunology disease cardiovascular disease focus cardiomyopathy heart failure thrombotic disease neuroscience focus neuropsychiatry neurodegenerative neuroinflammation disease work expand pipeline registrational asset addition position support continue innovation expand treatment option different disease base differentiate research platform broad portfolio pipeline come autologous cart cell therapie approve cell therapie distinct target continue build leadership space expand manufacturing capacity explore innovative technology dualtargete cart allogenic approach advance multiple nextgeneration asset include new target rapidly expand immunology include lupus multiple sclerosis strong position protein degradation field advance pipeline expansive library asset registrational trial additional clinical phase study study preclinically grow platform potential disease position deliver approximately ind year prove track record rapidly advance pipeline growth market product increase sustain productivity enable identify highquality candidate increase probability reach patient need specifically ambition deliver approximately ind year increase success rate firstinhuman trial approval approximately iii reduce timeline achieve median year firstinhuman trial approval strategy help ensure maintain strong legacy scientific innovation bring firstin class andor bestinclass treatment patient accelerate speed commercial model successful revenue inline brand new product portfolio continue grow demonstrate strong execution strategy remain focused wellresourced cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave oncology mechanism develop treatment option refractory oncology patient encourage investigational subcutaneous formulation opdivo potential bring enhanced benefit patient decade positive registrational datum inhouse continue drive adoption opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent strengthen portfolio opdualag treatment melanoma potential expand opportunity indication grow differentiate nsclc portfolio include launch augtyro include krazati acquire mirati demonstrate strategic fit oncology portfolio strengthen neuroscience portfolio plan acquisition karuna eliquis continue grow leverage good class clinical profile extensive real world datum remain number novel oral anticoagulant total prescription globally camzyos continue demonstrate benefit share longterm followup datum phase iii study immunology sotyktu key growth driver bm continue investment accelerate launch direct consumer advertising add field force support addition phase iii registrational clinical trial underway sotyktu psa sle sjgren syndrome able leverage lead capability hematological malignancy robust pipeline provide opportunity longterm growth offset impact current future patent expiry revlimid pomalyst look cell therapy franchise continue explore new indication breyanzi include treatment cll mcl indication cll approve cart available patient population reblozyl advance new indication ongoing registrational trial chronic anemia associate myelofibrosis evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio strategy extend discovery development delivery transformative medicine help patient prevail disease understand future employee communitie planet business inextricably link environmental social governance esg strategy seek mobilize capability resource positively impact community live work serve world work transform patient live science operate effective governance uncompromise quality compliance high ethical standard deliver mission value central company found believe drive longterm business value heart living purpose enable leader differencemaker generation come acquisition divestiture license arrangement detail information significant acquisition divestiture collaboration license arrangement refer item financial statement supplementary datum note alliance note acquisition divestiture license arrangement result operation regional revenue composition change revenue follow year end december dollar million change foreign exchangeb united states international othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period revenue united states revenue decrease primarily low revlimid sale drive previously disclose generic erosion increase patient receive free drug product revlimid less extent pomalyst bristol myers squibb patient assistance foundation separate independent entity bms donate product partially offset increase demand inline product new product portfolio average net selling price remain flat compare international international revenue decrease primarily revlimid eliquis generic erosion low average net selling price foreign exchange impact partially offset increase demand opdivo new product portfolio single country outside contribute total revenue business typically seasonal gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus reduction provision product sale prior period result change estimate million million respectively reduction provision drive nonus revision clawback amount drive vat recoverable estimate gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment percentage increase primarily high government channel mix high gtn adjustment percentage nonus gtn adjustment percentage increase primarily continued pricing pressure product revenue year end december dollar million change inline product eliquis nonus opdivo nonus orencia nonus pomalystimnovid nonus yervoy nonus sprycel nonus mature product nonus total inline product nonus year end december dollar million change new product portfolio reblozyl nonus opdualag nonus abecma nonus zeposia nonus breyanzi nonus camzyo nonus sotyktu nonus onureg nonu inrebic nonus augtyro nonus total new product portfolio nonus total inline product new product portfolio nonus year end december dollar million change recent loe productsa revlimid nonus abraxane nonus total recent loe product nonu total revenue nonus change excess recent loe product include product significant expect decline revenue prior reporting period result loe eliquis apixaban oral factor inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy revenue increase primarily high demand international revenue decrease primarily low average net selling price generic erosion canada exclude foreign exchange impact revenue decrease follow expiration regulatory exclusivity eliquis europe court decision find apixaban compositionof matter patent relate spc invalid generic manufacturer begin market generic version eliquis portugal seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe recently france norway sweden court hold bms favor confirm validity composition matter patent relate spc country believe innovative science eliquis strength intellectual property defend infringement refer item financial statementsnote legal proceeding contingenciesintellectual property information opdivo nivolumab fully human monoclonal antibody bind nkt cell approve anticancer indication include bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc gastric esophageal cancer ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent revenue increase high demand multiple indication less extent high average net selling price high demand relate follow indication opdivoyervoy combination nsclc gastric esophageal bladder cancer international revenue increase primarily high demand result core indication additional indication launch partially offset foreign exchange impact exclude foreign exchange impact revenue increase orencia abatacept fusion protein indicate adult patient moderate severe active psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate revenue increase primarily high demand international revenue increase high demand partially offset foreign exchange impact exclude foreign exchange impact revenue increase bms aware orencia biosimilar market japan formulation additional patent expire pomalystimnovid pomalidomide proprietary distinct small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy revenue decrease increase number patient receive free drug product bristol myers squibb patient assistance foundation separate independent entity bms donate product partially offset high average net selling price international revenue increase high demand partially offset low average net selling price foreign exchange impact exclude foreign exchange impact revenue increase estimate minimum market exclusivity date august yervoy ipilimumab ctla immune checkpoint inhibitor yervoy monoclonal antibody treatment patient unresectable metastatic melanoma opdivoyervoy regiman approve multiple market treatment nsclc melanoma mpm rcc crc esophageal cancer revenue increase high average net selling price demand international revenue increase high demand result additional indication launch core indication partially offset low average net selling price foreign exchange impact exclude foreign exchange impact revenue increase sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml revenue decrease low average net selling price drive unfavorable gtn adjustment international revenue decrease low demand result generic erosion low average net selling price foreign exchange impact exclude foreign exchange impact revenue decrease bms enter settlement agreement certain party sell generic dasatinib product begin september early certain circumstance generic dasatinib product enter market japan composition matter patent extend treatment nonimatinibresistant cml generics approve indication mature product include product include lose exclusivity major market otc product royalty revenue mature product international revenue mature product decrease primarily low demand result continue generic erosion foreign exchange impact exclude foreign exchange impact revenue decrease reblozyl luspaterceptaamt erythroid maturation agent indicate treatment anemia adult patient transfusion dependent non transfusion dependent beta thalassemia require regular red blood cell transfusion adult patient low intermediaterisk mds ring sideroblast require red blood cell transfusion iii adult patient previous erythropoiesis stimulate agent use esanave low intermediaterisk mds require regular red blood cell transfusion regardless ring sideroblast status revenue increase primarily high demand opdualag nivolumab relatlimabrmbw combination nivolumab block antibody relatlimab lag blocking antibody indicate treatment adult pediatric patient year age old unresectable metastatic melanoma opdualag launch march abecma idecabtagene vicleucel bcma genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticyclic adp ribose hydrolase monoclonal antibody revenue increase primarily high demand enable additional manufacturing capacity zeposia ozanimod oral immunomodulatory drug treat relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult treat moderately severely active adult revenue increase primarily high demand breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma specify highgrade bcell lymphoma primary mediastinal large bcell lymphoma grade revenue double sale primarily high demand camzyos mavacamten cardiac myosin inhibitor indicate treatment adult symptomatic obstructive hcm improve functional capacity symptom camzyo launch april sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicate treatment adult moderatetosevere plaque psoriasis candidate systemic therapy phototherapy sotyktu launch september onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy revenue increase primarily high demand inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia revenue increase primarily high demand augtyro repotrectinib kinase inhibitor indicate treatment adult patient locally advanced metastatic rospositive nsclc augtyro launch december revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revlimid receive approval indication hematological malignancy include lymphoma mds revenue decrease primarily generic erosion increase number patient receive free drug product bristol myers squibb patient assistance foundation separate independent entity bms donate product less extent low average net selling price international revenue decrease primarily generic erosion european country foreign exchange impact exclude foreign exchange impact revenue decrease certain party grant volumelimite license sell generic lenalidomide begin march pursuant license generic enter expect enter market volumelimite quantity generic lenalidomide japan generic lenalidomide product enter market global revenue revlimid expect decline range approximately billion billion abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer revenue increase primarily higher brand sale result lower authorize generic sale estimate endus demand pursuant sec consent order describe sec consent order monitor inventory level hand wholesaler distribution channel outside direct customer distribution channel disclose product level inventory excess month hand expect demand subject certain limited exception december distribution channel september nonus distribution channel generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product year end december factor influence estimate include generic erosion seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process camzyos available restrict program call camzyos rem program product distribution limit rem certify pharmacy enrol pharmacy dispense patient authorize receive camzyos revlimid pomalyst distribute primarily contract pharmacy lenalidomide rem pomalyst rem program respectively proprietary riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand current quarter subject certain limited exception quarterly report form expense year end december dollar million change cost product sell marketing sell administrative research development acquire iprd amortization acquire intangible asset incomeexpense net total expense change excess exclude amortization acquire intangible asset cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share foreign currency hedge settlement gain loss impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost cost product sell exclude amortization acquire intangible asset cost product sell increase million primarily high inventory cost million drive product mix cart cell therapy cost high royalty profit share million low hedging settlement gain million partially offset elimination puerto rico excise tax million low inventory purchase price adjustment million marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion cost proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense decrease million primarily time charitable give million cash settlement turn point unvested stock award million partially offset high advertising promotion cost result additional new product launch million site exit cost million research development research development activity include research early discovery preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement research development expense decrease million primarily cost relate unwind inventory purchase price adjustment clinical use million cash settlement turn point unvested stock award million partially offset purchase priority review voucher million acquire iprd acquire iprd expense comprise upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval acquire iprd charge detailed table year end december dollar millions mavacamten right buyout note orum upfront payment note mavacamten royalty extinguishment note dragonfly milestone optin license fee evotec designation optin license fee bridgebio upfront collaboration fee prothena optin license fee zenas upfront license fee immatic upfront license optin fee note acquire iprd refer item financial statement supplementary datanote alliance note acquisition divestiture license arrangement additional information amortization acquire intangible asset amortization acquire intangible asset decrease million primarily abraxane market product right fully amortize fourth quarter incomeexpense net incomeexpense net change billion primarily litigation settlement equity investment item discuss year end december dollar million interest expense royalty licensing income royalty income divestiture equity investment lossesincome net integration expense loss debt redemption divestiture gain litigation settlement investment income provision restructure contingent consideration incomeexpense net interest expense decrease additional debt maturity refer item financial statement supplementary datanote financing arrangement information royalty increase primarily high keytruda royalty refer item financial statement supplementary datanote acquisition divestiture license arrangement information equity investment generate low loss compare fair value adjustment investment readily determinable fair value refer item financial statement supplementary datanote financial instrument fair value measurement information integration expense decrease low consulting fee implement celgene integration initiative relate process system loss debt redemption result early redemption longterm debt billion divestiture gain result certain mature product right divest investment income increase primarily high interest rate litigation settlement include million income relate settlement million income relate nimbus tyk program change control provision partially offset million expense record connection beigene settlement litigation settlement include amount relate commercial dispute license supply obligation matter intellectual property promotional practice matter refer item financial statementsnote incomeexpense net provision restructuring include exit cost primarily relate certain restructuring activity include new plan discuss item financial statement supplementary datanote restructure income taxis year end december dollar million earning income taxis provision income taxis effective tax rate impact specify item effective tax rate exclude specify item effective tax rate decrease primarily impact specify item summarize follow nongaap financial measure section significant impact include million defer income tax benefit follow receipt nonus tax ruling deductibility statutory impairment subsidiary investments million high tax benefit attribute foreign currency net operating loss carryforward iii million valuation allowance reversal relate unrealized equity investment loss million tax benefit result revaluation basis intangible asset internally transfer streamline legal entity structure celgene acquisition million tax reserve release relate mead johnson splitoff transaction exclude impact specify item effective tax rate decrease primarily revise guidance deductibility certain research development expense reduce income taxis attributable pretax income approximately million primary reason million reduction previously estimate income taxis finalization federal income tax return favorable jurisdictional earning mix partially offset iii million impact change puerto rico tax decree eliminate previously creditable excise tax million low income tax reserve reversal income tax reserve reversal include million relate celgene irs audits million tax position effectively settle bms tax year exclude mead johnson relate amount specify lapse statute limitation celgene tax year refer item financial statement supplementary datanote income taxis additional information december member state voted unanimously adopt directive implement pillar global minimum tax rule give member state december implement directive national legislation certain jurisdiction operate oecdg inclusive framework enact legislation adopt subset rule effective january remain rule effective january rule associate legislative change significantly impact tax provision result operation implementation pillar currently expect increase effective tax rate exclude specify item approximately nongaap financial measure nongaap financial measure nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative past future operating result item exclude nongaap earning relate eps information company believe relate ordinary course company business reflect company underlie business performance similar charge gain recognize prior period likely reoccur future period include amortization acquire intangible asset include product right generate significant portion ongoing revenue recur intangible asset fully amortize unwind inventory purchase price adjustment iii acquisition integration expense restructuring cost accelerated depreciation impairment property plant equipment intangible asset cost acquire priority review voucher vii divestiture gain loss viii stock compensation result acquisitionrelate equity award pension legal contractual settlement charge equity investment contingent value right fair value adjustment include fair value adjustment attribute limited partnership equity method investment income result change control nimbus therapeutic tyk program xii amortization fair value adjustment debt acquire celgene exchange offer item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate certain significant tax item exclude impact result nonus tax ruling deductibility statutory impairment subsidiary investment release income tax reserve relate mead johnson splitoff transaction internal transfer intangible asset streamline legal entity structure subsequent celgene acquisition provide international revenue priority product exclude impact foreign exchange calculate foreign exchange impact convert currentperiod local currency financial result prior period average currency rate compare adjust amount currentperiod result reconciliation nongaap measure comparable gaap measure include exhibit form file february incorporate reference nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understand underlying financial performance facilitate comparison current past future period information intend consider isolation substitute relate financial measure prepare accordance gaap comparable similarly title measure present company possible difference method item adjust encourage investor review financial statement publiclyfile report entirety rely single financial measure specify item follow year end december dollar million inventory purchase price accounting adjustment intangible asset impairment site exit cost cost product sell employee compensation charge site exit cost marketing sell administrative iprd impairment priority review voucher inventory purchase price accounting adjustment employee compensation charge site exit cost research development amortization acquire intangible asset interest expensea equity investment lossesgain net integration expense loss debt redemption divestiture gain litigation settlement provision restructure incomeexpense net increase pretax income income taxis item income taxis attribute internal transfer intangible asset income tax reserve release attribute mead johnson income taxis attribute nonus tax rule income taxis increase net earning include amortization purchase price adjustment celgene debt reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bms gaap specify item nongaap weightedaverage common share outstanding diluted diluted earning share attributable bms gaap specify item nongaap financial position liquidity capital resource net debt position follow december dollar million cash cash equivalent marketable debt security current marketable debt security noncurrent total cash cash equivalent marketable debt security shortterm debt obligation longterm debt net debt position liquidity capital resource regularly assess anticipate work capital need debt leverage ratio level debt maturity capital expenditure requirement dividend payout potential share repurchase future investment acquisition order maximize shareholder return efficiently finance ongoing operation maintain flexibility future strategic transaction regularly evaluate capital structure ensure financial risk adequate liquidity access low cost capital efficiently manage lead issuance additional debt security repurchase debt security prior maturity issuance repurchase common stock believe exist cash cash equivalent marketable debt security cash generate operation year require issuance commercial paper sufficient satisfy anticipate cash need year include dividend capital expenditure milestone payment work capital income taxis restructure initiative repurchase common stock debt maturity approximately billion debt repurchase redemption tender offer december net debt position decrease billion primarily drive billion cash provide operation partially offset billion dividend payment common stock repurchase billion capital expenditure february enter billion day senior unsecured delay draw term loan facility provide bridge financing plan acquisition karuna rayzebio facility drawn acquisition close prior plan issuance debt security draw repay follow issuance security amount outstanding february information plan acquisition refer item financial statement supplementary datum note acquisition divestiture license arrangement issue aggregate principal billion debt net proceed acquisition mirati january general corporate purpose addition billion debt mature repay refer item financial statement supplementary datum note finance arrangement information share repurchase program authorize board director allow repurchase bm common stock share effect open market privately negotiate transaction compliance rule exchange act include rule trading plan share repurchase program obligate repurchase specific number share specific expiration date suspend discontinue time repurchase approximately million share common stock billion include approximately million share billion asr agreement december board director approve increase billion share repurchase authorization bms common stock remain share repurchase capacity bms share repurchase program billion december refer item financial statement supplementary datanote equity additional information dividend payment billion billion dividend pay common share quarter dividend authorize quarterly basis board director commercial paper program issue maximum billion unsecured note maturity day date issuance commercial paper borrowing outstanding december december fiveyear billion revolve credit facility expire january extendable annually year consent lender january extend credit facility january additionally february enter billion day revolve credit facility facility provide customary term condition financial covenant provide backup liquidity commercial paper borrowing borrowing outstanding revolve credit facility december investment portfolio include marketable debt security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement supplementary datum note finance arrangement information capital expenditure annual capital expenditure approximately billion million expect approximately billion continue capital expenditure connection expansion cell therapy manufacturing capability research development facilityrelate activity contractual obligation offbalance sheet arrangement normal course business enter contract commitment obligate payment future information obligation relate debt income taxis lease arrangement provide item financial statement supplementary datanote accounting policy recently issue accounting standard note financing arrangement note income taxis note lease respectively commit aggregate billion potential contingent future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict certain agreement provide salesbased milestone aggregate billion obligate pay achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statement supplementary datanote alliance note acquisition divestiture license arrangement information offbalance sheet arrangement material reasonably likely material financial condition result operation credit rating december follow announcement acquire karuna rayzebio standard poor downgrade bms longterm credit rating stable longterm credit outlook change shortterm standard poor credit rating downgrade longterm credit rating reflect standard poor anticipation high debt leverage follow announce acquisition partially offset improvement business strength february moody confirm bms longterm shortterm prime rating negative longterm credit outlook collectively current longterm credit rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm credit rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business million increase cash flow provide operating activity compare result billion low income tax payment primarily revise guidance deductibility certain research development expense million high noncustomer collection primarily royalty interest litigation settlement impact partially offset million low net customer collection net rebate discount million high payment primarily additional inventory requirement invest activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase proceed business divestiture include royalty sale maturity marketable security sale equity investment upfront contingent milestone payment license arrangement billion increase cash flow investing activity compare result billion change marketable debt security hold million low divestiture proceed partially offset acquisition turn point billion net cash acquire financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing proceed exercise stock option issuance longterm debt borrowing billion decrease cash financing activity compare result billion change net debt position primarily billion issuance debt connection acquisition mirati low debt maturitie million billion low share repurchase partially offset million low proceed stock option exercise recently issue accounting standard recently issue accounting standard refer item financial statement supplementary datanote accounting policy recently issue accounting standard sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy concern sale direct customer purpose comply consent include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly affect financial condition result operation require difficult subjective complex judgment need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow step model identify customer contract identify contract performance obligation iii determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience follow category gtn adjustment involve significant estimate judgment information obtain external source refer item financial statement supplementary datanote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country customer offer cash discount incentive prompt payment generally approximate invoice sale price account receivable reduce estimate cash discount time sale discount typically take customer month medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss market exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information acquisition intangible asset valuation certain judgment determine transaction account acquisition asset business combination determine substantially fair value gross asset acquire transaction concentrate single asset group similar asset transaction treat acquisition asset evaluate input process output associate acquire set activity asset asset transaction include input substantive process significantly contribute ability create output transaction treat acquisition business account business combination acquisition method accounting require asset acquire liability assume generally record fair value acquisition date excess consideration fair value net asset acquire record goodwill estimate fair value require significant judgment assumption transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date expense alternative future use addition product development milestone expense achievement identifiable intangible asset measure respective fair value acquisition date generally engage independent thirdparty valuation firm assist determine fair value asset acquisition date fair value asset estimate discount cash flow model model require use follow significant estimate assumption identification product candidate sufficient substance require separate recognition estimate revenue operate profit relate commercial product product candidate eligible patient price market share estimate future revenue probability success unapproved product candidate additional indication commercial product resource require complete development approval product candidate time regulatory approval exclusivity appropriate discount rate product market participant income tax rate allocation expect synergies product believe fair value record intangible asset acquire base reasonable estimate assumption consider fact circumstance acquisition date impairment amortization longlive asset include intangible asset longlive asset include intangible asset property plant equipment review impairment event change circumstance indicate carry asset recoverable annually iprd intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include change competitive landscape early expect loss market exclusivity pricing reduction adverse regulatory change clinical study result delay failure obtain regulatory approval initial follow indication unanticipate development cost inability achieve expect synergy result cost saving avoidance high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation carrying value longlive asset exceed fair value asset write fair value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use estimate useful life longlive asset subjective require significant judgment patent life future plan external market factor longlive asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration depreciation amortization impairment charge include cost product sell research development expense million million billion refer item financial statement supplementary datanote goodwill intangible asset discussion analysis impairment charge income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance million billion december net valuation allowance million federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statement supplementary datanote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statement supplementary datanote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency product pipeline development program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year opdivo investigational compound market product represent approximately expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow latestage new indication development market product development latestage pipeline february product indication date developments ono alliance partner opdivo japan announce submit supplemental application opdivo intravenous infusion human antihuman monoclonal antibody japan expand use december treatment unresectable urothelial carcinoma partial change approve item manufacture marketing approval application base result substudy phase iii checkmate trial announce fda accept sbla opdivo combination cisplatinbase chemotherapy firstline treatment adult patient unresectable metastatic urothelial carcinoma bladder december application base result phase iii checkmate trial fda grant application priority review status assign pdufa goal date april announce ema validate type variation application opdivo combination cisplatinbase chemotherapy firstline treatment adult patient unresectable metastatic october urothelial carcinoma application base result phase iii checkmate trial application validation confirm submission complete begin ema centralized review opdivo procedure announce fda approval opdivo adjuvant treatment adult pediatric patient year october older completely resect stage iib iic melanoma approval base phase iii checkmate trial melanoma announce approval opdivo monotherapy adjuvant treatment adult adolescent august year age old stage iib iic melanoma undergone complete resection approval base result phase iii checkmate trial ono alliance partner opdivo japan announce receive supplemental approval opdivo intravenous infusion human antihuman monoclonal antibody japan expand use treatment malignant mesothelioma exclude malignant pleural mesothelioma partial change malignant mesothelioma november approve item manufacture marketing approval supplemental approval base result investigatorinitiate clinical phase viola trial product indication date development announce followup result phase iii checkmate trial demonstrate sustain eventfree survival promise overall survival trend cycle opdivo combination platinumbase chemotherapy neoadjuvant treatment patient resectable nsclc regardless pdl expression october levels neoadjuvant opdivo chemotherapy show improvement pathologic complete response major pathologic response chemotherapy pdl patient population safety profile opdivobase regimen consistent pdl subgroups nsclc announce disclosure datum phase iii checkmate trial evaluate perioperative regimen neoadjuvant opdivo chemotherapy follow surgery adjuvant opdivo patient resectable stage iia iiib nsclc show statistically significant clinically mean improvement october primary efficacy endpoint eventfree survival assess blinded independent central review compare neoadjuvant chemotherapy placebo follow surgery adjuvant placebo announce approval opdivo combination platinumbase chemotherapy neoadjuvant treatment resectable nsclc high risk recurrence adult patient tumor cell pdl expression june approval base result phase iii checkmate trial nsclc ono alliance partner opdivo japan announce japan ministry health labour welfare march supplemental approval opdivo plus chemotherapy neoadjuvant treatment patient resectable nsclc approval base result phase iii checkmate trial announce result phase iii checkmate trial evaluate opdivo combination docetaxel patient advance metastatic castrationresistant prostate cancer meet primary endpoint radiographic progressive free survival final analysis overall survival interim analysis prostate cancer july safety concern report base recommendation dmc company decide discontinue study opdivo announce datum phase iii checkmate trial evaluate subcutaneous nivolumab coformulate halozyme proprietary recombinant human hyaluronidase compare intravenous opdivo patient advance metastatic clear cell rcc receive prior systemic therapy demonstrate non january inferiority coprimary endpoints cavgd timeaveraged opdivo serum concentration day cminss trough serum concentration steady state compare intravenous opdivo addition subcutaneous nivolumab display noninferior objective response rate assess blinded independent central review versus intravenous opdivo announce fouryear followup result checkmate trial evaluate opdivo combination cabometyx cabozantinib sunitinib patient previously untreate advanced metastatic rcc january continued superior progressionfree survival objective response rate patient treat rcc opdivo plus cabometyx sunitinib regardless risk classification base imdc score superior overall survival observe patient treat combination announce phase iii checkmate noninferiority trial evaluate subcutaneous formulation opdivo coformulate halozyme therapeutic proprietary recombinant human hyaluronidase rhpuh subcutaneous nivolumab compare intravenous opdivo patient advance metastatic clear cell renal cell carcinoma ccrcc receive prior systemic therapy meet coprimary october pharmacokinetic endpoint key secondary endpoint subcutaneous nivolumab demonstrate noninferiority cavgd timeaveraged opdivo serum concentration day cminss trough serum concentration steady state compare opdivo studys coprimary endpoint additionally subcutaneous nivolumab show noninferior objective response rate assess blinded independent central review opdivo key secondary endpoint safety profile subcutaneous nivolumab consistent formulation announce threeyear result phase iii checkmate trial demonstrate significant sustain clinical benefit opdivo adjuvant treatment patient surgically resect highrisk muscle february invasive continuous improvement diseasefree survival nonurothelial tract recurrencefree survival distant metastasisfree survival second progressionfree survival compare placebo allrandomize patient patient tumor cell express pdl product indication date development announce eightyear datum phase iii checkmate trial evaluate opdivo plus yervoyversus sunitinib continue demonstrate longterm survival result reduce risk death patient previously untreate advanced metastatic rcc regardless imdc risk rcc january group patient treat opdivo plus yervoy maintain superior survival durable response benefit compare receive sunitinib patient intermediate poorrisk prognostic factor randomize patient announce phase iii checkmate trial evaluate opdivo plus yervoy compare investigator choice chemotherapy firstline treatment patient microsatellite instability high mismatch repair deficient metastatic colorectal cancer meet dual primary endpoint progression free survival pfs assess blinded independent central review bicr prespecific interim analysis study ongoing assess second dual primary endpoint pfs bicr patient receive opdivo plus yervoy compare opdivo line therapy secondary metastatic colorectal opdivoyervoy cancer january endpoint addition datum phase iii checkmate trial show combination opdivo plus yervoy reduce risk disease progression death versus chemotherapy firstline treatment patient microsatellite instabilityhigh mismatch repair deficient metastatic colorectal cancer msihdmmr mcrc compare chemotherapy announce sixyear result phase iii checkmate trial demonstrate longterm durable september survival benefit opdivo plus yervoy compare chemotherapy firstline treatment patient metastatic nsclc regardless pdl expression level nsclc announce fouryear followup result phase iii checkmate trial demonstrate durable longterm survival benefit opdivo plus yervoy cycle chemotherapy compare june cycle chemotherapy previously untreated patient metastatic nsclc announce japan ministry health labour welfare grant manufacturing marketing approval reblozyl mdsrelated anemia approval base result global phase iii january command trial phase iii medalist study japanese phase study study mds red blood cell transfusionindependent lowrisk mds patient announce update result primary analysis phase iii command trial compare reblozyl versus epoetin alfa treatment anemia erythropoiesis stimulate agent esanave mds december patient lowerrisk myelodysplastic syndrome require red blood cell transfusion reblozyl confirm positive outcome interim analysis superior efficacy durability compare esa announce fda approval reblozyl treatment anemia previous erythropoiesis stimulate agent use esanave adult patient low intermediaterisk mds august require regular red blood cell transfusion approval base phase iii command trial announce approval reblozyl treatment adult patient anemia associate non beta thalassemia march transfusiondependent beta thalassemia approval base result phase study phase iii relativity trial evaluate fixeddose combination nivolumab relatlimab treatment microsatellite stable metastatic colorectal cancer patient disease progress following prior line therapy metastatic disease discontinue opdualag colorectal cancer december futility base plan analysis conduct independent datum monitor committee determine trial unlikely meet primary endpoint completion recommendation stop study base safety concern announce chmp ema recommend approval abecma early line therapy tripleclass expose relapse refractory multiple myeloma chmp recommendation review authority approve medicine recommendation approval abecma multiple myeloma january base phase iii karmma study abecma demonstrate superiority standard regimen significantly improve progressionfree survival wellestablishe safety profile lowgrade occurrence cytokine release syndrome neurotoxicity product indication date development announce result preplanne final progressionfree survival analysis pivotal phase iii open december label global randomize control karmma study demonstrate significantly improve pfs maintain abecma compare standard regimen reduction risk disease progression death announce japan ministry health labour welfare grant manufacturing marketing approval supplemental new drug application additional indication abecma patient relapse abecma multiple myeloma december refractory multiple myeloma receive prior therapy include immunomodulatory agent proteasome inhibitor anticd antibody approval base interim analysis phase iii karmma study april announce alliance partner seventy bio fda accept sbla abecma treatment adult patient relapse refractory multiple myeloma receive immunomodulatory agent proteasome inhibitor anticd monoclonal antibody announce datum phase iii daybreak radiance trial show year followup patient treat zeposia relapse multiple sclerosis free sixmonth confirm disability progression finding demonstrate treatment zeposia result low rate progression independent relapse activity relapseassociate worsen key driver disease progression zeposia multiple sclerosis october permanent disability multiple sclerosis announce interim readout phase iiib enlighten trial show clinically meaningful improvement cognitive functioning compare baseline year zeposia treatment half patient early relapse multiple sclerosis announce fda accept sbla breyanzi expand new indication include treatment adult patient relapse refractory follicular lymphoma relapse refractory mantle cell lymphoma mcl bruton tyrosine kinase inhibitor fda grant application priority review assign pdufa goal date breyanzi relapse refractory breyanzi relapse refractory mcl addition japan ministry health labour welfare accept company supplemental january new drug application snda breyanzi treatment relapse refractory relapse refractory application breyanzi japan base result transcend study relapse refractory mcl application breyanzi base result mcl cohort transcend nhl study breyanzi lymphoma announce disclosure primary analysis result highrisk secondline cohort phase transcend study evaluate breyanzi patient relapse refractory follicular lymphoma december demonstrate complete response patient highrisk relapse refractory treat secondline setting announce fda accept sbla breyanzi expand current indication include treatment adult patient relapse refractory chronic lymphocytic leukemia small lymphocytic november lymphoma receive prior bruton tyrosine kinase inhibitor bcell lymphoma inhibitor fda grant application priority review assign pdufa goal date march announce approval breyanzi treatment adult patient diffuse large bcell lymphoma high grade bcell lymphoma primary mediastinal large bcell lymphoma grade relapse month completion refractory firstline chemoimmunotherapy approval base result phase iii transform trial product indication date development announce result poetyk pso lte trial sotyktu treatment adult patient moderateto severe plaque psoriasis clinical response rate maintain continuous treatment modify nonresponder imputation response psoriasis area severity index pasi year october continuous sotyktu treatment sotyktu consistent safety profile increase adverse event adverse event new safety signal sotyktu plaque psoriasis announce approval sotyktu treatment adult moderatetosevere plaque psoriasis candidate systemic therapy approval base phase iii poetyk pso poetyk march pso clinical trial additional data poetyk pso longterm extension trial announce longterm followup result phase iii valorhcm lte trial demonstrate consistent impact oral treatment severely symptomatic obstructive hcm patient show nearly patient treat camzyos continue trial septal reduction therapy week treatment august announce result phase iii explorerlte trial show treatment camzyos camzyos obstructive hcm demonstrate sustained improvement leave ventricular outflow tract obstruction symptom probnp level patient symptomatic obstructive hcm new safety signal observe announce approval camzyos treatment symptomatic new york heart association class june iiiii obstructive hcm adult patient approval base result phase iii explorer hcm valorhcm trials augtyro announce fda approval augtyro treatment patient rospositive locally advanced nsclc november repotrectinib metastatic nsclc approval base phase iii trident trial ema validate marketing authorization application repotrectinib treatment ros tyrosine kinase inhibitor tkinave pretreate adult patient rospositive locally advanced repotrectinib nsclc january metastatic nsclc tkinave pretreate adult pediatric patient year old ntrkpositive locally advanced metastatic solid tumor application base result registrational phase iii trident trial care study announce alliance partner janssen pharmaceuticals inc johnson johnson company prospective indication milvexian investigational oral factor xia inhibitor grant fast track designation fda designation cover indicationseeking study phase iii milvexian thrombosis librexia development program librexia stroke librexia acs librexia dose patient announce fda grant breakthrough therapy designation bms potential firstin class oral lysophosphatidic acid receptor lpa antagonist treatment progressive pulmonary progressive pulmonary fibrosis ppf breakthrough therapy designation base result global randomized phase bm lpa fibrosis october study assess safety efficacy bms treatment versus placebo people live idiopathic pulmonary fibrosis ipf ppf stable background use antifibrotic ipf cohort andor select immunosuppressive ppf cohort allow special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forward look statement meaning section security act section exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product business development strategy relation ability realize project benefit acquisition alliance business development activity impact pandemic epidemic operation development commercialization product potential law regulation low drug price market action take private government payer manage drug utilization contain cost expiration patent datum protection certain product include assumption ability retain marketing exclusivity certain product outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement include particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require applicable law undertake obligation publicly update revise forwardlooke statement result new information future event change circumstance date item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward purchase local currency option contract manage risk primarily arise certain intercompany sale purchase transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate non dollar currency foreign currency forward contract offset exposure designate hedge foreign currency forward contract hedge foreign currency exposure net investment certain international affiliate designate hedge net investment estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange contract million million december december respectively reduce earning remain life contract crosscurrency swap contract manage risk arise longterm debt denominate euros hedge company net investment foreign subsidiary estimate appreciation underlie currency hedge level dollar variable hold constant increase fair value crosscurrency swap contract million december decrease million december respectively additional information refer item financial statement supplementary datanote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use cross currency swap contract designate manage risk arise longterm debt denominate euros hedge company net investment foreign subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase longterm interest rate december december decrease fair value longterm debt billion billion respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statement supplementary datanote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product solda marketing sell administrative research development acquire iprd amortization acquire intangible asset incomeexpense net total expense earning income taxis provision income taxis net earning noncontrolle interest net earning attributable bms earning common share basic dilute exclude amortization acquire intangible asset consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable debt security receivables inventory current asset total current asset property plant equipment goodwill intangible asset defer income taxis marketable debt security noncurrent asset total asset liability current liability shortterm debt obligation account payable current liability total current liability defer income taxis longterm debt noncurrent liability total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bms shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earningsloss net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge divestiture gain royalty acquire iprd equity investment lossesgain net contingent consideration fair value adjustment adjustment change operate asset liability receivable inventory account payable rebate discount income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable debt security purchase marketable debt security proceed sale equity investment security capital expenditure divestiture proceed acquisition payment net cash acquire net cash investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend stock option proceed net net cash financing activity effect exchange rate cash cash equivalent restrict cash increasedecrease cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year cash cash equivalent restrict cash end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard nature operation basis consolidation bristolmyer squibb company bms company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end definition capitalize term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function consistent bmss operational structure chief executive officer ceo chief operating decision maker manage allocate resource global corporate level manage allocate resource global corporate level enable ceo assess overall level resource available well deploy resource function therapeutic area regional commercial organization research development project line overarch longterm corporatewide strategic goal product franchise basis determination single segment consistent financial information regularly review ceo purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine accounting acquisition impairment intangible asset chargeback cash discount sale rebate return adjustment legal contingency income taxis actual result differ estimate cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper treasury bill money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition equity investment equity investment readily determinable fair value record fair value change fair value record incomeexpense net equity investment readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value equity investment readily determinable fair value record incomeexpense net bms hold investment limited partnership primarily invest earlystage life science company limit partnership investment measure proportionate share net asset value underlie investment hold limited partnership practical expedient investment typically redeemable distribution liquidation underlie asset limit partnership investment own company account equity method accounting ability exercise significant influence operate financial decision investee maintain proportional share investee net income loss equity investment account equity method include incomeexpense net equity investment readily determinable fair value equity investment account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost net realizable value property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software range year acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition asset acquire meet definition business primarily significant process acquire substantially relative fair value allocate single asset transaction account asset acquisition business combination goodwill record addition asset acquisition acquire inprocess research development iprd asset alternative future use charge acquire iprd goodwill iprd intangible asset fair value acquire intangible asset determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success finitelive intangible asset include license market product right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize goodwill tested annually impairment assess qualitative factor determine likely fair value net asset carry amount example qualitative factor assess include bmss share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annually frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value derivative derivative instrument recognize asset liabilitie fair value consolidate balance sheet classify current longterm base scheduled maturity instrument derivative designate hedge assess inception quarterly determine highly effective offset change cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately effective portion change fair value derivative designate cash flow hedge report accumulate comprehensive loss subsequently recognize earning consistent underlying hedged item derivative long highly effective hedge company discontinue hedge account prospectively earning impact relate discontinued cash flow hedge hedge ineffectiveness material period present hedged forecast transaction probable occur gain loss reclassify accumulated comprehensive loss earning derivative designate hedge adjust fair value current earning company use derivative instrument foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate realize unrealized gain loss hedge include foreign currency translation accumulate comprehensive loss derivative cash flow exception net investment hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item cash flow related net investment hedge classify investing activity restructure restructuring charge recognize result action streamline operation realize synergy acquisition reduce number facility estimate impact restructuring plan include future termination benefit integration expense exit cost require judgment actual result vary estimate restructure charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur revenue recognition refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance research development acquire iprd research development cost expense incur clinical study certain research cost recognize service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner acquire iprd expense include upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval company acquire iprd type transaction follow year end december dollar millions alliance note inlicense arrangement note acquire iprd advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense approximately billion billion foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive incomeloss income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax effect global intangible lowtaxed income certain foreign subsidiary recognize income tax provision period tax arise tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement recently adopt accounting standard fair value measurement june fasb issue amend guidance measure fair value equity security subject contractual restriction prohibit sale equity security guidance clarify contractual restriction sale equity security consider unit account equity security consider measure fair value guidance clarify entity separate unit account recognize measure contractual sale restriction amendment require follow disclosure equity security subject contractual sale restriction fair value equity security subject contractual sale restriction reflect consolidated balance sheet nature remain duration restriction circumstance cause lapse restriction amend guidance effective january prospective basis early adoption permit guidance adopt january adoption impact consolidate financial statement business combination october fasb issue amend guidance accounting contract asset contract liability contract customer business combination guidance intend address inconsistency relate recognition acquire contract liability payment term effect subsequent revenue recognize acquisition date entity account relate revenue contract accordance exist revenue recognition guidance generally assess acquiree apply recognition measurement financial statement guidance adopt january adoption impact consolidate financial statement recently issue accounting standard adopt income taxis december fasb issue amend guidance income tax disclosure guidance intend provide additional disaggregation effective income tax rate reconciliation income tax payment disclosure amend guidance effective annual period beginning january apply prospective basis early adoption permit segment reporting november fasb issue amend guidance improvement reportable segment disclosure revise guidance require public entity disclose significant segment expense regularly review chief operating decision maker codm include public entity single reportable segment amend guidance effective fiscal year begin january interim period begin january retrospective basis early adoption permit note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent total revenue period present product sell principally wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product consider customer obtain legal title product infusion cell therapie bms obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage gross revenue follow year end december mckesson corporation cencora inc know amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return gtn adjustment gtn adjustment attribute commercial arrangement manage healthcare organization government program medicare medicaid program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcomebase pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month gtn adjustment reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement bms outlicense intellectual property party performance obligation arrangement include license additional performance obligation supply product request party iii collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include incomeexpense net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include incomeexpense net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenues fee allocation license supply represent consideration expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelated obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include incomeexpense net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information follow table summarize disaggregation revenue product region year end december dollar millions inline product eliquis opdivo orencia pomalystimnovid yervoy sprycel mature brand total inline product new product portfolio reblozyl opdualag abecma zeposia breyanzi camzyos sotyktu onureg inrebic augtyro total new product portfolio total inline product new product portfolio recent loe productsa revlimid abraxane total recent loe product total revenue united states international otherb total revenue recent loe product include product significant expect decline revenue prior reporting period result loe include royalty alliancerelate revenue product sell bmss regional commercial organization contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize asc asc contract asset reduce receivable increase period underlie sale occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million million million consist primarily revise estimate gtn adjustment relate prior period sale royalty outlicense arrangement sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region bms refer collaboration alliance partner alliance partner common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bmss contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bmss ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bmss ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development regulatory approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent regulatory approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include acquire iprd expense royalty contingent consideration payable bms alliance partner relate divestiture business include incomeexpense net earn payment bms alliance partner present cash flow operating activity upfront milestone payment present cash flow investing activity select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development acquire iprd incomeexpense net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election statement earning classification amount attributable payment party systimmune december bms systimmune inc systimmune announce global strategic collaboration codevelopment cocommercialization bispecific topoisomerase inhibitorbase antibody drug conjugate target egfr currently evaluate phase clinical trial metastatic unresectable nsclc party jointly develop commercialize blbd profit research development commercialization cost share systimmune responsible development commercialization manufacture mainland china responsible manufacturing certain drug supply outside mainland china bms receive royalty net sale bms responsible development commercialization rest world systimmune receive royalty net sale transaction effective february include upfront payment million include acquire iprd quarter bms obligate pay billion achievement contingent development regulatory salesbase milestone pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment record deferred income amortize incomeexpense net eliquis commercial product commencement alliance upfront payment subsequent contingent milestone proceed amortize expect period bms copromotion obligation market exclusivity period party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea certain small country pfizer commercialization right bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment bridgebio bms bridgebio commence collaboration develop commercialize bbp shp inhibitor oncology transaction include upfront payment million expense acquire iprd bridgebio eligible receive contingent development regulatory salesbase milestone million royaltie global net sale exclude certain market bridgebio responsible funding complete ongoing bbp phase monotherapy combination therapy trial bms lead fund development commercial activity bridgebio option codevelop bbp receive high royalty seventy bio bms seventy bio jointly develop commercialize novel diseasealtering gene therapy product candidate target bcma collaboration include right bms license antibcma product result collaboration right seventy bio participate development commercialization license product result collaboration codevelopment profit share exchange reduction milestone payment iii salesbase milestone royalty payable seventy bio commercialization license product result collaboration seventy bio decline exercise codevelopment profit sharing right bms exercise option license idecabtagene vicleucel abecma seventy bio elect participate development commercialization abecma term collaboration amend transfer substantially manufacture obligation bms eliminate exus milestone royalty payable seventy bio abecma fda approve abecma treatment relapse refractory multiple myeloma net product sale abecma million million million relate profit sharing cost million million million respectively cost reimbursement material eisai bms eisai commence exclusive global strategic collaboration codevelopment cocommercialization morab selective folate receptor alpha antibodydrug conjugate investigate endometrial ovarian lung breast cancer morab currently phase iii clinical trial solid tumor party jointly develop commercialize morab canada europe russia japan china certain country asiapacific region collaboration territory eisai responsible global manufacturing supply profit research development commercialization cost share collaboration territory bms responsible development commercialization outside collaboration territory pay royalty sale million upfront collaboration fee expense acquire iprd bms obligate pay billion achievement contingent development regulatory salesbase milestone cost reimbursement material note acquisition divestiture license arrangement acquisition mirati january bms acquire mirati commercial stage target oncology company pipeline clinical commercial oncology medicine acquisition bms add commercialize lung cancer medicine krazati clinical asset include mrtx krazati bestinclass inhibitor krasgc mutation approve fda secondline treatment patient nsclc clinical development combination inhibitor firstline therapy patient nsclc indication mrtx potential firstinclass mtacooperative prmt inhibitor phase development bms gain access promising clinical preclinical stage asset include additional kra inhibitor enable program bms acquire issue outstanding share mirati common stock share allcash transaction total consideration billion billion net estimate cash acquire mirati stockholder receive nontradeable contingent value right share mirati common stock hold potentially worth share cash total value approximately billion payout contingent value right subject fda acceptance nda mrtx treatment specific indication seven year closing transaction transaction account business combination asset acquire liability assume recognize fair value acquisition date purchase price allocation consideration transfer asset acquire liability assume finalize acquisition fund combination cash hand debt proceed karuna december bms enter definitive merger agreement acquire karuna clinicalstage biopharmaceutical company drive discover develop deliver transformative medicine people live psychiatric neurological condition acquisition provide bms right karuna lead asset karxt xanomelinetrospium karxt antipsychotic novel mechanism action differentiate efficacy safety currently review fda treatment schizophrenia adult pdufa date september karxt registrational trial adjunctive therapy exist standard care agent schizophrenia treatment psychosis patient alzheimer disease bms acquire issue outstanding share karuna common stock share allcash transaction total consideration billion accounting treatment business combination asset acquisition determine period transaction close transaction expect close half subject customary closing condition include approval karuna stockholder receipt regulatory approval acquisition fund primarily future debt proceed rayzebio december bms enter definitive merger agreement acquire rayzebio clinicalstage radiopharmaceutical therapeutic rpt company actiniumbase rpt solid tumor acquisition provide bms right rayzebio actiniumbase radiopharmaceutical platform lead asset ryz phase iii development treatment gastroenteropancreatic neuroendocrine tumor bms acquire issue outstanding share rayzebio common stock share allcash transaction total consideration billion transaction expect account business combination anticipate close half subject fulfillment customary closing condition include receipt require regulatory approval acquisition fund primarily future debt proceed orum november bm acquire right orum orm program preclinical development orm anticd antibodyenable gspt degrader receive fdas clearance phase treatment patient acute myeloid leukemia highrisk myelodysplastic syndrome consideration include upfront payment million contingent development milestone payment million upfront payment expense acquire iprd turning point bms acquire turning point billion cash billion net cash acquire turning point clinicalstage precision oncology company pipeline investigational medicine design target common mutation alteration drive cancer growth acquisition provide bms right turn point lead asset repotrectinib clinical preclinical stage asset repotrectinib approve fda november market brand augtyro transaction account business combination asset acquire liability assume recognize fair value acquisition date total consideration acquisition consist follow dollar million cash consideration outstanding share cash consideration equity award consideration pay unvested stock award total consideration allocate include unvested equity award million expense marketing sell administrative million expensed research development purchase price allocation result follow amount allocate asset acquire liability assume acquisition date base respective fair value summarize dollar million cash cash equivalent current asset intangible asset defer income tax asset noncurrent asset defer income tax liability current liability identifiable net asset acquire goodwill total consideration allocate intangible asset include billion iprd allocate repotrectinib augtyro estimate fair value iprd asset determine income approach valuation method goodwill result primarily recognition defer tax liability deductible tax purpose result turn point operation include consolidated financial statement commence august material historical financial result acquire entity significant divestiture follow table summarize financial impact divestiture include royalty income include incomeexpense net revenue pretax earning relate divestiture material period present exclude divestiture gain loss net proceed divestiture gainslosse royalty income dollar millions diabete business royalty mature product othera total include cash proceed million divestiture gain million relate sale mature product cheplapharm diabete business bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance consideration transaction include tiere royalty payment range base net sale royalty million million million bm transfer percentage future royalty right amylin onglyza farxiga net product sale party result transfer royalty income associate product reduce million million million mature product manufacturing operation bms agree sell manufacturing facility syracuse new york lotte corporation account business heldforsale result million impairment charge record cost product sell asset liability reclassify heldforsale include current asset current liability million million respectively december january bms complete sale result cash proceed million receive december licensing arrangement royalty licensing income follow table summarize financial impact keytruda royalty tecentriq royalty upfront licensing fee milestone product obtain commercial approval include incomeexpense net year end december dollar million keytruda royalty tecentriq royalty upfront licensing fee contingent milestone income amortization defer income biohaven sublicense income royalty total lianbio mavacamten october bms reacquire right mavacamten china certain asian territory lianbio transaction result million acquire iprd charge include cash transfer million carrying value previously establish license intangible asset keytruda patent license agreement bms ono party global patent license agreement merck relate merck antibody keytruda agreement merck obligate pay ongoing royalty global sale keytruda december pay january december company grant certain right respective patent portfolio pertain payment royalty share bms ono percent allocation respectively adjust party legal fee tecentriq patent license agreement bms ono party global patent license agreement roche group relate tecentriq roche antipdl antibody agreement roche obligate pay singledigit royalty worldwide net sale tecentriq december royalty share bms ono consistent exist agreement inlicense arrangement immatic bm obtain global exclusive license immatic tcr bispecific program study oncology bms immatic collaborate development bms responsible commercialization worldwide include strategic decision regulatory responsibility funding manufacture immatic option cofund development exchange enhance royalty payment andor copromote transaction include upfront payment million expense acquire iprd immatic eligible receive contingent development regulatory salesbase milestone million royaltie global net sale agenu bms obtain global exclusive license agenu proprietary agen bispecific antibody program block tigit additional target agen study oncology bms responsible development subsequent commercialization agen relate product worldwide include strategic decision regulatory responsibility funding manufacturing transaction include payment million expense acquire iprd addition agenu eligible receive contingent development regulatory salesbase milestone billion royalty global net sale dragonfly bms obtain global exclusive license dragonfly interleukin investigational immunotherapy program phase development milestone achieve result million payment dragonfly expense acquire iprd bms notify dragonfly terminate global exclusive license relate dragonfly program right revert dragonfly bms amend term license arrangement pay party million extinguish future royalty obligation relate camzyos mavacamten prior fda approval april result acquire iprd charge note incomeexpense net year end december dollar million interest expense royalty licensing income note royalty income divestiture note equity investment lossesgain net note integration expense note loss debt redemption note divestiture gain note litigation settlement investment income provision restructure note contingent consideration incomeexpense net litigation settlement beigene settlement bms beigene ltd beigene enter agreement settle ongoing dispute claim party include related abraxane license supply agreement relate arbitration proceeding describe note legal proceeding contingency agreement provide termination contractual relationship party include license supply arrangement pertain revlimid vidaza effective december subject beigene right continue sell remain inventory date consideration bms agree transfer million beigene ordinary share common stock hold share subscription agreement beigene result million expense include incomeexpense net expense determine base closing price share date transfer addition remain beigene ordinary share own bms share subscription agreement convert american depository share subsequently sell astrazeneca settlement bms enter agreement astrazeneca settle outstanding claim party ctla litigation pdl antibody litigation describe note legal proceeding contingency astrazeneca pay aggregate million bm payment september subject sharing arrangement ono danafarber bms share approximately million net present value million reflect incomeexpense nimbus change control income bms nimbus enter settlement resolve legal claim business interest pertain nimbus tyk inhibitor result million income include incomeexpense settlement provide bms receive additional amount contingent development regulatory approval salesbase milestone change control proceed receive nimbus relate tyk inhibitor takeda acquire ownership nimbus tyk inhibitor approximately billion upfront proceed plus contingent salesbased milestone aggregate billion result million income relate change control provision include incomeexpense contingent consideration contingent consideration include million fair value adjustment result change trade price contingent value right issue celgene acquisition contractual obligation pay contingent value right terminate january fda approve lisocel jcar december note restructure restructuring plan bms commence restructuring plan accelerate delivery medicine patient evolve streamline enterprise operating model key area manufacturing commercial function ensure operating model support appropriately align company strategy invest key priority change primarily include transform operation accelerate pipeline delivery enhance commercial operating model iii establish responsive manufacturing network expand cell therapy manufacturing capability charge approximately billion expect incur consist primarily employee termination cost less extent site exit cost include impairment accelerate depreciation property plant equipment celgene acquisition plans restructure integration plan initiate realize expect cost synergy result cost saving avoidance acquisition celgene myokardia turning point plan company expect incur charge approximately billion cumulative charge approximately billion recognize date include integration planning execution expense employee termination benefit cost accelerate stockbased compensation contract termination cost shutdown cost associate site exit remain charge primarily relate celgene system integration follow provide charge relate restructuring initiative type cost year end december dollar million restructuring plan celgene acquisition plan total charge employee termination cost termination cost provision restructure integration expense accelerate depreciation asset impairment shutdown cost net total charge cost product sell marketing sell administrative research development incomeexpense net total charge follow summarize charge spend related restructuring plan activity year end december dollar million liability january provision restructuringa payment foreign currency translation liability december include reduction liability result change estimate million million note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision income taxis effective tax rate reconciliation effective tax rate statutory federal income tax rate follow earning income taxis dollar million earning income taxis nonus total statutory rate gilti net foreign derive intangible income deduction foreign tax effect certain operation ireland puerto rico switzerland nonus tax rule internal transfer intangible asset federal valuation allowance federal state foreign contingent tax matter federal researchbase credit charitable contribution inventory contingent value rights puerto rico excise tax credit state local taxis net valuation allowance foreign total provision income taxis gilti net foreign derive intangible income deduction include benefit approximately million revise guidance deductibility certain research development expense foreign tax effect certain operation ireland puerto rico switzerland include impact earning mix million benefit impact foreign currency net operating loss carryforward nonus tax ruling include million defer income tax benefit deductibility statutory impairment subsidiary investment internal transfer intangible asset streamline legal entity structure subsequent celgene acquisition result tax benefit federal valuation allowance include million reversal relate unrealized equity investment loss federal state foreign contingent tax matter include tax benefit relate lapse statute effectively settle contingent tax matter million million federal researchbase credit include credit research development orphan drug credit include revise estimate finalization prior year tax return fair value adjustment contingent value right taxable tax deductible puerto rico impose excise tax gross company purchase price good sell bmss manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize bmss provision income taxis excise tax incur december bms amend exist puerto rico decree eliminate excise tax increase puerto rico tax rate effective tax year begin january extend bmss tax grant additional year defer taxis valuation allowance component defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal capital loss net operating loss tax credit milestone payment license fee capitalize research expenditure total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability acquire intangible asset goodwill total defer tax liability defer tax assetsliabilitie net recognize deferred income taxis asset noncurrent defer income taxis liabilitie noncurrent total bms indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply bms remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable foreign net operating loss carryforward include impact nonus tax ruling deductibility statutory impairment subsidiary investment federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million exist follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity investment fair value adjustment federal net operating loss carryforward change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisitionsdispositionsliquidation net nonus rate change balance end year certain foreign net operating loss relate valuation allowance utilize eliminate result internal legal entity restructuring income tax payment billion billion billion connection enactment tcja require pay onetime transition tax elect pay period year permit tcja remain amount payable follow million billion million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follows exclude interest penalty year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense amount reflect beneficial impact tax settlement include settlement discuss bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense previously disclose bms receive notice propose adjustment irs relate transfer pricing tax issue tax year bms disagree irss position continue work cooperatively irs resolve issue bms enter irs administrative appeal process resolve matter time final resolution complex matter uncertain material impact bmss financial statement tax position year unrelated matter enter administrative appeal process considered effectively settle reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy japan note earningsloss share year end december amount million share datum net earning attributable bms weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning common share basic diluted total number potential share common stock exclude diluted earning share computation antidilutive impact material note financial instrument fair value measurement financial instrument include cash cash equivalent marketable debt security equity investment account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value sofr yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract fair value level equity investment adjust characteristic specific security adjust contractual sale restriction equity investment subject contractual sale restriction material december level unobservable input little market datum available level financial liability consist acquisition relate contingent consideration success payment relate undeveloped product right transfer level year end december financial asset liability measure fair value recur basis summarize december december dollar million level level level level level level cash cash equivalent money market security marketable debt security certificate deposit commercial paper corporate debt security treasury security derivative asset equity investment derivative liability contingent consideration liability contingent value right acquisition relate contingent consideration marketable debt security amortize cost marketable debt security approximate fair value security mature year december year december equity investment follow summarize carry equity investment december dollar million equity investment readily determinable fair value equity investment readily determinable fair value limited partnership equity method investment total equity investment follow summarize activity relate equity investment change fair value equity investment include incomeexpense net year end december dollar million equity investment readily determine fair value net loss recognize net gain recognize investment sell net unrealized loss recognize investment hold equity investment readily determinable fair value upward adjustment impairment downward adjustment equity net incomeloss affiliate total equity investment lossesgain cumulative upwards adjustment cumulative impairment downward adjustment base observable price change equity investment readily determinable fair value hold december million million respectively qualify hedge nonqualifye derivative cash flow hedge bms enter foreign currency forward purchase local currency option contract foreign exchange contract hedge certain forecast intercompany inventory sale certain foreign currency transaction objective foreign exchange contract reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value foreign exchange contract designate cash flow hedge temporarily record accumulate comprehensive loss aocl reclassify net earning hedge item affect earning typically month december assume market rate remain constant contract maturity expect reclassify pretax gain million cost product sell foreign exchange contract aocl month notional outstanding foreign currency exchange contract primarily billion euro contract billion japanese yen contract december bms enter crosscurrency swap contract hedge exposure foreign currency exchange rate risk associate longterm debt denominate euro contract convert interest payment principal repayment longterm debt dollar euro designate cash flow hedge unrealize gain loss contract report aocl reclassify incomeexpense net period hedge debt affect earning notional crosscurrency interest rate swap contract associate longterm debt denominate euros billion december cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis earning impact relate discontinued cash flow hedge hedge ineffectiveness material period present foreign currency exchange contract designate cash flow hedge offset exposure certain foreign currency denominate asset liability earning change fair value derivative recognize earning occur net investment hedge crosscurrency swap contract foreign currency forward contract million december designate hedge currency exposure bms net investment foreign subsidiary contract fair value change record foreign currency translation component aocl relate offset derivative asset liability consolidated balance sheet notional outstanding crosscurrency swap foreign currency forward contract primarily attribute japanese yen million euro million december year end december amortization gain relate portion net investment hedge exclude assessment effectiveness material fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend align debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt derivative cash flow exception net investment hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item cash flow related net investment hedge classify investing activity follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value designate cash flow hedge foreign exchange contract crosscurrency swap contract designate net investment hedge foreign exchange contract crosscurrency swap contract designate fair value hedge interest rate swap contract designate hedge foreign currency exchange contract total return swap contractsc include current asset noncurrent asset include current liability noncurrent liability total return swap contract enter hedge change fair value certain deferred compensation liability follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost incomeexpense cost incomeexpense cost incomeexpense dollar million product sell net product sell net product sell net interest rate swap contract crosscurrency swap contract foreign exchange contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive incomeloss year end december dollar million derivative qualify cash flow hedge foreign exchange contract gainloss recognize comprehensive incomeloss reclassify cost product sell crosscurrency swap contract gainloss recognize comprehensive income reclassify incomeexpense net forward start interest rate swap contract loss reclassify incomeexpense net derivative qualify net investment hedge crosscurrency swap contract gainloss recognize comprehensive incomeloss foreign exchange contract gainloss recognize comprehensive incomeloss nonderivative qualify net investment hedge nonus dollar borrowing gainloss recognize comprehensive incomeloss company dedesignate remain net investment hedge debt denominate euros million represent effective portion foreign exchange loss remeasurement debt note finance arrangement shortterm debt obligation include december dollar millions nonus shortterm borrowing current portion longterm debt total longterm debt current portion longterm debt include december dollar million principal value note note note note note note note note euro note note note note note note note note note note note note note euro note note note note note note note note note note note note note note note note note note note note note convertible debt total december dollar million principal value adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost unamortized purchase price adjustment celgene debt total current portion longterm debt longterm debt total fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument february enter billion day senior unsecured delay draw term loan facility provide bridge financing plan acquisition karuna rayzebio facility drawn acquisition close prior plan issuance debt security draw repay follow issuance security amount outstanding february bms issue aggregate principal billion fix rate unsecured senior note company net proceed offer finance acquisition mirati january general corporate purpose bms issue aggregate principal billion fix rate unsecured senior note net proceed billion note rank equally right payment bmss exist future senior unsecured indebtedness redeemable time vary specify redemption price plus accrue unpaid interest bms purchase aggregate principal billion certain debt security billion cash series tender offer redemption connection transaction million loss debt redemption recognize base carry value debt include incomeexpense net bms purchase aggregate principal billion certain debt security approximately billion cash series tender offer redemption connection transaction million loss debt redemption recognize base carry value debt include incomeexpense net repayment note maturity aggregate billion billion billion interest payment billion billion billion aggregate maturity longterm debt year follow billion billion billion billion billion interest payment relate longterm debt year follow billion billion billion billion billion credit facility december bms fiveyear billion revolve credit facility expire january extendable annually year consent lender january extend credit facility january additionally february enter billion day revolve credit facility facility provide customary term condition financial covenant provide backup liquidity bms commercial paper borrowing borrowing outstanding revolve credit facility december available financial guarantee provide form bank overdraft facility standby letter credit performance bond billion december standby letter credit guarantee issue financial institution support obligation include sale product hospital foreign ministry health bond custom duty vat note receivables december dollar million trade receivable chargeback cash discount allowance expect credit loss net trade receivables alliance royalty vat receivables nonus receivables sell nonrecourse basis billion billion billion aggregate receivable pharmaceutical wholesaler represent approximately total trade receivables december respectively change allowance expect credit loss chargeback cash discount follow year end december dollar million balance begin year provisiona utilization balance end year include provision expect credit loss million million million note inventory december dollar million finished good work process raw packaging material total inventory inventory noncurrent asset total inventory include fair value adjustment result celgene acquisition approximately million december note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states international total depreciation expense million million million note lease lease facility office research development storage distribution purpose comprise approximately total lease obligation lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year year lease contain specific renewal option period range year year notice renew provide advance lease expiration automatic renewal advance notice require period cover option extend lease include noncancellable lease term exercise option determine reasonably certain certain lease contain termination option provide flexibility terminate lease ahead expiration sufficient advance notice period cover option terminate lease include non cancellable lease term exercise option determine reasonably certain judgment require assess renewal termination option reasonably certain exercise factor consider contractual term compare current market rate leasehold improvement expect significant value cost terminate lease importance facility operation cost determine variable base index rate include measurement real estate lease liability variable cost include real estate taxis insurance utility common area maintenance operating cost implicit rate lease readily determinable incremental borrowing rate apply portfolio approach discount real estate lease liability remain lease obligation comprise vehicle research development facility operate party management direction vehicle lease term vary country term generally year year follow table summarize component lease expense year end december dollar million operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse asset liability follow december dollar million noncurrent asset current liability noncurrent liability total liability future lease payment noncancellable operating lease december follow dollar million total future lease payment imputed interest total lease liability rightofuse asset obtain exchange new operating lease obligation million rightofuse asset impairment charge million cash pay amount include measurement operating lease liability million million million undiscounte lease obligation operating lease commence million december obligation primarily relate research development facility construct lessor expect ready use supplemental balance sheet information relate lease follow december weight average remain lease term year year weight average discount rate note goodwill intangible asset goodwill change carry amount goodwill follow december dollar million begin balance turning point acquisition currency translation adjustment end balance intangible asset intangible asset consist follow december estimate gross carry accumulate intangible gross carry accumulate intangible dollar million useful life amount amortization asset net amount amortization asset net license year acquire market product right year capitalize software year iprd total november billion iprd previously allocate repotrectinib augtyro transfer acquire market product right obtain fda approval refer note acquisition divestiture license arrangement information relate turning point acquisition december bms agree pay million shareholder impact biomedicine extinguish remain contingent milestone obligation record acquire market product right inrebic million establish applicable deferred tax liability million pay january amortization expense intangible asset billion billion billion future annual amortization expense intangible asset expect approximately billion billion billion billion billion intangible asset impairment charge million million billion impairment charge primarily result decision discontinue development investigational compound connection prioritization current pipeline opportunitie million iprd impairment charge investigational compound record research development expense primarily result change clinical timeline expect launch date competitive landscape compound study potential treatment hematologic disease acquire acquisition celgene charge represent partial writedown carry value base estimate fair value determine discount cash flow projection million iprd impairment charge record research development expense follow decision discontinue development investigational compound connection prioritization pipeline opportunity compound study potential treatment fibrotic disease acquire acquisition celgene charge represent writedown base estimate fair value determine discount cash flow projection inrebic regulatory approval milestone million achieve result million increase acquire market product right intangible asset establish applicable defer tax liability impairment charge million recognize cost product sell carry value asset exceed project undiscounted cash flow asset charge equal excess asset carrying value estimate fair value discount cash flow projection note supplemental financial information december dollar million income taxis research development contract asset restrict casha current asset december dollar million equity investment operating lease inventory pension postretirement research development restrict casha receivables convertible note noncurrent asset restrict cash consist fund restrict annual company contribution define contribution plan escrow litigation settlement cash restrict withdrawal general use contractually legally restrict december dollar million rebate discount income taxis employee compensation benefit research development dividend interest royalty operating lease current liability december dollar million income taxis pension postretirement operating lease defer income defer compensation noncurrent liability note equity accumulate capital excess common stock treasury stock par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance december net earning comprehensive incomeloss cash dividend declareda share repurchase stock compensation distribution balance december net earning comprehensive incomeloss cash dividend declareda share repurchase stock compensation distribution balance december net earning comprehensive incomeloss cash dividend declareda share repurchase stock compensation convertible debt distribution balance december cash dividend declare common share bms share repurchase program authorize board director allow repurchase share effect open market privately negotiate transaction compliance rule exchange act include rule trading plan share repurchase program obligate repurchase specific number share specific expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method generally fund cash hand december board director approve increase billion share repurchase authorization bms common stock remain share repurchase capacity bms share repurchase program billion december bm repurchase approximately million share common stock billion bm enter asr agreement repurchase million share common stock billion addition share repurchase program bm repurchase million share common stock billion bm enter asr agreement repurchase million share common stock billion addition share repurchase program bm repurchase million share common stock billion asr agreement fund cash onhand total number share repurchase asr agreement base volumeweighted average price bms common stock term asr transaction discount subject adjustment pursuant term condition asr agreement component comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge recognize comprehensive incomeloss reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial gainslosse amortizationb settlementsb pension postretirement benefit marketable debt security unrealize lossesgain foreign currency translation comprehensive incomeloss include cost product sell incomeexpense net refer note financial instrument fair value measurement information include incomeexpense net accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translationa accumulate comprehensive loss include foreign currency net investment hedge gain million million december december respectively note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan certain employee define benefit pension plan net periodic benefit cost define benefit pension plan million million million year end december respectively change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow year end december dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize noncurrent asset current liability noncurrent liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow december dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation follow december discount rate rate compensation increase interest credit rate weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit cost follow year end december discount rate expect longterm return plan asset rate compensation increase interest credit rate yield high quality corporate bond match duration benefit obligation determine discount rate ftse pension discount curve develop discount rate plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial gain loss relate plan benefit obligation primarily result change discount rate postretirement benefit plan comprehensive medical group life benefit provide substantially bm retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory postretirement benefit plan obligation million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material plan asset fair value pension plan asset asset category follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company transfer level year end december investment practical expedient consist primarily multiasset fund redeemable daily weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense individual plan investment allocation determine local fiduciary committee composition total asset pension plan december broadly characterize allocation equity security debt security investment contribution estimate future benefit payment company estimate annual contribution future benefit payment expect material saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match define contribution plan expense approximately million million million note employee stock benefit plan shareholder approve stock award incentive plan plan replace previous equity plan plan authorize award form incentive stock option nonqualifie stock option stock appreciation right sar restrict stock restrict stock unit rsus dividend equivalent performance share unit psus market share unit msus stockbased award december plan plan authorize grant equity award plan provide million share authorize grant plus share recapture forfeiture termination award previous equity award plan subject adjustment accordance term plan december million share available award million equity award outstanding stock option rsus msus psus share generally issue treasury stock satisfy bmss obligation plan prior equity award plan plan executive officer employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant sar grantee surrender exercisable right receive common stock andor cash measure excess market price common stock award exercise price bms grant stock option sar year end december option outstanding year generally vest ratably year option grant replacement option hold celgene option holder acquisition celgene provide cliff vest andor long shorter vest period rsus grant executive officer employee subject restriction continuous employment generally vest occur ratably fouryear period grant date subject accelerate vest specify circumstance stock unit right receive stock end specify vest andor deferral period stock unit vote right bms grant nonforfeitable stock unit nonemployee director msus grant executive officer vest condition continuous employment occur ratably year subject accelerate vest specify circumstance number share issue vest msus determine base specified payout factor require market price share specify measurement date grantdate share price market condition award grant prior attainment high payout factor calculate share price measurement date divide share price award date result high percentage payout msus maximum target number msus award grant prior share price payout factor calculate average closing price grant date measurement date trading day immediately precede grant date measurement date psus grant executive officer threeyear performance cycle grant target number stock unit subject adjustment number share issue psus vest determine base achievement specify performance goal performance condition base bmss threeyear relative total shareholder return compound annual growth rate relative peer group company market condition award grant threeyear total shareholder return relative peer group company prior range maximum target number psus vest condition continuous employment occur anniversary grant date subject accelerate vest specify circumstance stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million cost product sell marketing sell administrative research development incomeexpense net total stockbase compensation expense income tax benefita income tax benefit exclude excess tax benefit sharebase compensation award vest exercise million million million follow table summarize stock compensation activity year end december stock option rsus msus psus weighted weight weight weight average number average number average number average number exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million option share rsus fair value msus fair value psus fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december expect vest dollar million restrict stock unit market share unit performance share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share rsus msus psus fair value awards vest rsus replacement awards rsus msus psus total intrinsic value stock option exercise fair value rsus approximate close market price bmss common stock grant date adjust unit eligible accrual dividend equivalent fair value msus estimate grant date monte carlo simulation fair value psus estimate grant date portion relate relative total shareholder return measure monte carlo simulation remain portion base closing market price bmss common stock grant date adjust unit eligible accrual dividend equivalent take account probability satisfy performance condition grant date follow table summarize significant outstanding exercisable option december weightedaverage number option remain contractual life weightedaverage aggregate intrinsic value range exercise price million year exercise price share million outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december trading day note legal proceeding contingency bms certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer partner supplier service provider licensee licensor employee shareholder matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement legal proceeding significant bms believe significant material describe bms believe matter specifically note material adverse effect financial position liquidity bms believe substantial claim andor defense matter outcomes bms legal proceeding contingency inherently unpredictable subject significant uncertainty assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material bms financial position result operation cash flow particular period furthermore failure successfully enforce bms patent right likely result substantial decrease respective product revenue generic competition note bms unable assess outcome respective matter able estimate possible loss range loss potentially result matter contingency accrual recognize probable liability incur relate loss reasonably estimate development legal proceeding matter cause change amount previously accrue evaluated reporting period discussion bmss tax contingency note income taxis intellectual property eliquis europe lawsuit file generic company country europe seek revocation compositionofmatter patent spc relate eliquis trial preliminary proceeding hold certain case croatia october bms file request commercial court zagreb preliminary injunction prohibit teva offer store sell generic eliquis product croatia decision pende finland court grant request preliminary injunction prohibit teva offer store sell generic eliquis product finland obtain price reimbursement trial teva challenge validity finnish compositionofmatter patent relate spc conclude july decision pende france trial hold teva challenge validity french compositionofmatter patent relate spc decision issue june confirm validity reject teva claim teva appeal decision ireland court grant request preliminary injunction prohibit teva make offering put market andor andor import stocking aforesaid purpose generic eliquis product trial court preliminary injunction decision subsequently affirm appeal irish court appeal trial teva challenge validity irish compositionofmatter patent relate spc conclude july decision deliver december irish trial court find irish compositionofmatter patent relate spc invalid bms intend appeal irish trial court decision netherlands request preliminary injunction prevent atrisk generic launch sandoz stada teva prior trial validity dutch compositionofmatter patent spc initially deny low court judgment issue august dutch court appeal overturn decision low court issue preliminary injunction sandoz stada teva order company recall generic eliquis product dutch market trial challenge bring sandoz teva respectively validity dutch compositionofmatter patent relate spc take place october january decision pende norway trial hold teva challenge validity norwegian compositionofmatter patent relate spc decision issue confirm validity reject teva claim teva appeal decision hearing appeal schedule april portugal patent validity infringement proceeding pende multiple company seek market generic version eliquis trial mylan challenge validity portuguese compositionofmatter patent schedule commence february early september teva launch generic eliquis product portuguese market september company file request preliminary injunction teva portuguese intellectual property court romania request preliminary injunction teva initially deny low court january romania court appeal overturn decision low court issue preliminary injunction teva prohibit teva offer store sell generic eliquis product romania spain trial teva challenge validity spanish compositionofmatter patent relate spc hold october decision deliver january spanish court find spanish compositionofmatter patent relate spc invalid bms intend appeal spanish court decision sweden trial hold teva challenge validity swedish compositionofmatter patent relate spc decision issue november confirm validity reject teva claim teva appeal decision hearing appeal schedule switzerland trial teva challenge validity swiss compositionofmatter patent relate spc hold november decision pende sandoz teva file lawsuit seek revocation compositionofmatter patent relate spc bms subsequently file counterclaim infringement action combine trial take place february judgment issue april judge find apixaban composition ofmatter patent relate spc invalid bms appeal judgment court appeal uphold low court decision october supreme court reject bms application appeal follow instance decision generic manufacturer begin market generic version eliquis addition challenge validity compositionofmatter patent relate spc pende denmark italy poland czechia slovakia hungary bulgaria greece lithuania generic manufacturer seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe inrebic september impact biomedicines inc impact receive notice letter teva notify bms impact file anda contain paragraph certification seek approval generic version inrebic challenge certain patent list orange book inrebic response october impact file patent infringement action teva district court district new jersey january party enter confidential settlement agreement case dismiss onureg bm receive notice letter accord healthcare inc accord msn laboratories private limited msn teva pharmaceuticals inc teva natco pharma limited natco respectively notify bm file anda contain paragraph certification seek approval generic version onureg challenge patent nos patent patent fda orange bookliste formulation patent cover onureg expire respectively response bms file patent infringement action accord msn teva natco district court district delaware case msn trial schedule begin september trial date schedule teva natco action november bms accord enter confidential settlement agreement case accord dismiss february apotex inc file request inter parte review ipr patent july uspto grant apotex request institute ipr patent discovery ongoing january party enter settlement agreement inter parte review terminate plavix australia sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc subsequently change apotex genrxapotex august genrxapotex file application federal court australia seek revocation sanofi australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court australia grant sanofi injunction subsidiary bms subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidated genrxapotex case august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid bms sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim genrxapotex appeal september court hold claim patent invalid march high court australia deny request bms sanofi hear appeal court decision case remand federal court proceeding relate damage seek genrxapotex bms genrxapotex settle genrxapotex case dismiss australian government intervene matter seek maximum damage million aud million plus interest split bms sanofi allege loss experience pay high price brand plavix period injunction place bms sanofi dispute australian government entitle damage trial conclude september april federal court issue decision dismiss australian government claim damage australian government appeal federal court decision appeal hearing conclude february june appeal court issue rule bms sanofi favor uphold low court decision december australian government grant leave appeal decision high court australia revlimid april celgene receive notice letter amneal pharmaceutical amneal notify celgene amneal file anda contain paragraph certification seek approval market generic version revlimid response january celgene initiate patent infringement action amneal district court district new jersey assert certain fda orange book list patent february party enter confidential settlement agreement case dismiss sprycel bm receive notice letter xspray pharma xspray nanocopoeia llc nanocopoeia handa oncology llc handa zydus pharmaceuticals zydus notify bms file application contain paragraph certification seek approval dasatinib product challenge fda orange bookliste monohydrate form patent expire february bms file patent infringement action xspray district court district new jersey bms file patent infringement action nanocopoeia district court district minnesota november bms file patent infringement action handa district court northern district california march minnesota court deny motion nanocopoeia file seek judgment base pleading june bms enter confidential settlement agreement handa settle outstanding claim litigation september bms enter confidential settlement agreement xspray settle outstanding claim litigation october bms enter confidential settlement agreement nanocopoeia settle outstanding claim litigation october bms file patent infringement action zydus district court district new jersey zeposia october actelion pharmaceuticals ltd actelion pharmaceutical inc actelion file complaint patent infringement united states district court district new jersey bms celgene allege infringement patent patent complaint allege sale zeposia infringe certain claim patent actelion seek damage trial date schedule pricing sale promotional practice litigation plavix state attorney general lawsuit bms certain sanofi entity defendant consumer protection action bring attorney general hawaii relate labeling sale andor promotion plavix february hawaii state court judge issue decision sanofi bms impose penalty total million million attribute bms sanofi bms appeal decision march hawaii supreme court issue decision reverse affirm trial court decision vacate penalty award remand case new trial penalty determination new bench trial conclude october decision pende product liability litigation bms party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit bms face unfiled claim involve product abilify bms otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court united states pursuant previously disclose master settlement agreement settlement relate court order vast majority case united states resolve dismiss inactive case remain pende state court new jersey case pende canada class action seven individual injury claim active certify class action quebec ontario onglyza bms astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza february judicial panel multidistrict litigation order federal onglyza case transfer mdl district court eastern district kentucky significant majority claim pende mdl pende coordinated proceed california superior court san francisco jccp jccp court grant summary judgment defendant march decision affirm california court appeal california supreme court decline review decision july mdl court grant defendant motion exclude plaintiff general causation expert january grant summary judgment august plaintiff file notice appeal december appeal remain pende sixth circuit bms global diabetes business divestiture bms sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca security litigation celgene security litigation begin march putative class action file celgene certain officer district court district new jersey celgene security class action complaint allege defendant violate federal security law make misstatement andor omission concern trial ge celgene outlook project sale otezla nda zeposia court consolidate action appoint lead plaintiff lead counsel coliaison counsel putative class february defendant file motion dismiss plaintiff amend complaint december court deny motion dismiss grant motion dismiss include claim arise allege misstatement ge court give plaintiff leave replead dismiss claim elect dismiss claim dismiss prejudice november court grant class certification respect remain claim march court grant defendant leave file motion summary judgment briefing complete june september court grant deny defendant motion summary judgment claim statement remain officer defendant claim celgene corporate statement court deny defendant motion prejudice grant defendant leave reraise issue october defendant file motion partial summary judgment celgene corporate statement april certain schwab management investment company behalf certain schwab fund file individual action district court district new jersey assert largely allegation celgene security class action remain defendant action schwab action july defendant file motion dismiss plaintiff complaint march court grant deny defendant motion dismiss consistent decision celgene security class action california public employee retirement system april calper action dfa investment dimensions group inc behalf certain fund american century mutual fund inc behalf certain fund july respectively dfa action american century action gic private limited september gic action file separate individual action district court district new jersey assert largely allegation celgene security class action schwab individual action remain defendant action october action consolidate pretrial proceeding schwab action court consolidate future direct action raise common question law fact schwab action consolidated schwab action october defendant file motion partial summary judgment consolidated schwab action trial date schedule celgene security litigation contingent value right litigation june action file bms district court southern district new york assert claim allege breach contingent value right agreement cvr agreement enter connection closing bms acquisition celgene corporation november entity claim successor trustee cvr agreement allege bms breach cvr agreement allegedly fail use diligent effort obtain fda approval lisocel breyanzi contractual milestone date allegedly avoid billion potential obligation holder contingent value right govern cvr agreement allegedly fail permit inspection record response request allege successor trustee plaintiff seek damage determine trial relief include interest attorney fee bms dispute allegation bms file motion dismiss allege successor trustee complaint failure state claim relief grant deny june february bms file motion dismiss complaint lack subject matter jurisdiction october allege celgene stockholder file complaint district court southern district new york assert claim behalf putative class celgene stockholder receive cvrs bms merger celgene violation section securities exchange act exchange act relate joint proxy statement action later consolidate action file court consolidated complaint file assert claim behalf class cvr acquirer bms merger celgene violation section securities act securities act sections exchange act complaint allege february joint proxy statement materially false misleading fail disclose bms allegedly intention obtain fda approval lisocel breyanzi applicable milestone date cvr agreement certain statement bms certain bms officer periodic sec filing earning call press release investor presentation december november materially false misleading reason defendant move dismiss complaint march court enter opinion order grant defendant motion dismiss complaint entirety claim section securities act section exchange act dismiss prejudice claim section exchange act dismiss leave file amend complaint plaintiff file april defendant move dismiss amend complaint briefing motion complete june motion currently pende court november allege purchaser cvrs file complaint supreme court state new york new york county assert claim behalf putative class cvr acquirer violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement defendant move stay action pende resolution federal action alternative dismiss complaint later file similar motion response amend complaint february court grant defendant motion dismiss case entirety november allege celgene stockholder file complaint superior court new jersey union county assert claim behalf separate putative class acquirer cvr acquirer bms common stock violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement celgene chairman chief executive officer defendant move stay action pende resolution federal action alternative dismiss complaint february court grant defendant motion stay decline reach merit defendant motion dismiss october plaintiff file motion vacate stay trial date schedule cvr litigation litigation ira litigation june bms file lawsuit department health human service center medicare medicaid services challenge constitutionality drugprice program ira program require pharmaceutical company like bms threat significant penalty sell certain medicine governmentdictate price august government select eliquis program lawsuit bms argue program violate fifth amendment require government pay compensation take property public use require pharmaceutical manufacturer provide medicine party price set government necessarily fall fair market value bms argue program violate amendment right free speech require manufacturer state agree price set government medicine maximum fair price determine negotiation true negotiation august bm file motion summary judgment october government file opposition bmss motion summary judgment crossmotion summary judgment thalomid revlimid litigation begin november certain putative class action lawsuit file celgene district court district new jersey allege celgene violate antitrust consumer protection unfair competition law allegedly secure exclusive supply contract allege purpose prevent generic manufacturer secure supply thalidomide active pharmaceutical ingredient allegedly refuse sell sample thalomid revlimid brand drug generic manufacturer allege purpose bioequivalence test necessary anda submit fda approval market generic version product allegedly bring unjustified patent infringement lawsuit order allegedly delay approval propose generic version thalomid revlimid andor allegedly enter settlement patent infringement lawsuit certain generic manufacturer allegedly anticompetitive effect plaintiff behalf putative class thirdparty payer seek injunctive relief damage lawsuit consolidate master action purpose march celgene reach settlement class plaintiff october court enter final order approve settlement dismiss matter settlement resolve certain claim certain entity opt settlement file new suit advance related theory describe certain consolidated coordinate suit describe pende march humana inc humana opted settlement file lawsuit celgene district court district new jersey humana complaint make largely claim allegation settle thalomid revlimid antitrust class action litigation complaint purport assert claim behalf humana subsidiary capacity include direct purchaser indirect purchaser seek thing treble punitive damage injunctive relief attorney fee cost celgene file motion dismiss humana complaint april court issue order deny celgene motion dismiss order address celgene argument certain humana claim bar statute limitation court order address celgene ground dismissal instead direct celgene present argument renew motion dismiss follow filing amend complaint humana file amend complaint celgene bm assert claim base additional factual allegation celgene bms subsequently file motion dismiss humana amend complaint august september court hold argument celgene bms motion trial date schedule united healthcare services inc uhs blue cross blue shield association bcbsm bcbsm inc health care service corporation hcsc blue cross blue shield florida inc cigna corporation cigna molina healthcare inc molina msp relate entity msp recovery claim series llc mspa claims llc maomso recovery llc series pmpi segregate series maomso recovery llc msp recovery claim series llc msp recovery claim prov series llc msp recovery claim caid series llc msp file lawsuit make largely claim allegation nowsettle class action litigation humana optout action uhs msp matter include additional claim relate copay assistance thalomid revlimid case pende district court district new jersey bcbsm voluntarily dismiss claim celgene bms motion dismiss humana amend complaint apply action action proceed describe respect humana optout action trial date schedule molina sue celgene bms san francisco superior court molina complaint make largely claim allegation settle class action litigation june san francisco superior court dismiss molinas claim molina later reassert district new jersey describe stay remain claim activity expect case disposition new jersey action certain entity opt nowsettle class action file summons relate action philadelphia county court common plea connection allegation humana optout entity action place deferred status pende development optout case november certain specialty pharmacy file action direct purchaser celgene bm certain generic manufacturer district court district new jersey action make largely claim allegation celgene bms respect revlimid settle class action litigation seek injunctive relief damage sherman antitrust act november putative class endpayor plaintiff file action celgene bms certain generic manufacturer district court district new jersey class complaint bring claim base celgene allegedly anticompetitive settlement revlimid patent litigation seek damage state antitrust consumer protection law injunctive relief federal antitrust law celgene bms generic defendant file consolidated motion dismiss action motion fully brief administratively terminate november pende rule celgene bms motion dismiss humana amend complaint trial date schedule october november healthcare systemsthe mayo clinic lifepoint corporate service intermountain health incfile new lawsuit celgene bms certain generic manufacturer make largely claim allegation celgene bms respect revlimid nowsettle class action litigation seek injunctive relief damage sherman antitrust act parallel state law action pende district court district new jersey trial date schedule msk contract litigation april memorial sloan kettere cancer center eureka therapeutics inc collectively plaintiff file complaint bms celgene juno collectively defendant june plaintiff file amend complaint plaintiff allege defendant breach license agreement allegedly fail use commercially reasonable effort develop manufacture commercialize certain chimeric antigen receptor product fail pay plaintiff run royalty worldwide sale abecma allegedly owe plaintiff license agreement defendant disagree plaintiff claim file motion dismiss amend complaint july january court grant defendant motion dismiss bms celgene remove case case juno continue trial date schedule pomalyst antitrust class action september certain health plan entity file action behalf putative class endpayor plaintiff celgene bm certain generic pharmaceutical manufacturer district court southern district new york class complaint assert claim federal antitrust law state antitrust consumer protection unjust enrichment law base allegation celgene bm engage anticompetitive conduct relate pomalidomide include allegedly engage fraud uspto acquisition patent relate use pomalidomide filing allege sham patent litigation generic pharmaceutical company seek market generic pomalidomide enter allegedly unlawful patent litigation settlement certain generic pharmaceutical company seek market generic pomalidomide december plaintiff file amend complaint add individual pomalyst patient plaintiff remove generic manufacturer defendant add individual defendant trial date schedule government investigation like pharmaceutical company bms certain subsidiary subject extensive regulation national state local authority country bms operate result bms time time subject governmental regulatory inquiry investigation threaten legal action proceeding possible criminal charge substantial fine andor civil penalty result government regulatory investigation environmental proceeding previously report bms party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity bms current site waste disposal reprocess facility operate party cercla remediation matter respect cercla remediation matter bm responsible state federal international law bm typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party bms accrue liability probable reasonably estimable bms estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise currentperiod audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate grosstonet rebate accrual medicaid medicare manage healthcare refer note revenue financial statement critical audit matter description fully disclose note financial statement company reduce gross product sale list price time revenue recognize expect chargeback discount rebate sale allowance product return refer grosstonet gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program mandate reduction list price chargeback cash discount reflect reduction receivables settle issuance credit customer rebate discount adjustment reflect liability settle cash payment certain gtn liability relate medicaid medicare manage healthcare organization rebate program gtn rebate accrual involve use significant assumption judgment calculation significant assumption judgment include consideration legal interpretation applicable law regulation historical claim experience payer channel mix current contract price unbilled claim claim submission time lag inventory level distribution channel give complexity involve determine significant assumption calculate certain gtn rebate accrual auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate gtn rebate accrual include follow evaluate appropriateness consistency company method assumption calculate gtn rebate accrual test effectiveness internal control review company estimation model include underlying assumption key input company process calculate gtn rebate accrual test mathematical accuracy gtn rebate accrual test significant assumption key input calculate gtn rebate accrual evaluate company ability estimate gtn rebate accrual accurately compare actual amount incur gtn rebate accrual historical estimate test overall reasonableness gtn rebate accrual record period end develop expectation comparison actual record balance involve audit professional industry quantitative analytic experience assist perform auditing procedure taxis unrecognize tax benefit liabilitie transfer pricing refer note income taxis financial statement critical audit matter description fully disclose note financial statement company recognize certain income tax benefit associate transaction operate company relate foreign affiliate income tax benefit estimate base transfer pricing agreement thirdparty transfer pricing study company judgment morelikelythannot benefit realize tax benefit ultimately realize company determine judgment accrue unrecognized tax benefit liability amount recognize unrecognized tax benefit liability relate transfer pricing significantly affect subsequent period factor change tax law identification additional relevant fact change company judgment measurement tax benefit ultimate settlement tax authority give complexity associate significant assumption judgment calculate unrecognized tax benefit liability relate transfer pricing auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate unrecognized tax benefit liability relate transfer pricing include follow evaluate appropriateness consistency company method assumption identification recognition measurement disclosure unrecognized tax benefit liability test effectiveness internal control review underlie assumption key input company process calculate unrecognized tax benefit liability obtain understand company relate party transaction transfer pricing policy test mathematical accuracy unrecognized tax benefit liability test completeness unrecognized tax benefit liability test reasonableness underlie tax position amount accrue selection unrecognized tax benefit liability review company evaluation relevant fact tax law associate tax position test significant assumption input calculate unrecognized tax benefit liability reference party datum information produce entity understand transfer pricing principle tax law inquire management evaluate company appropriately consider new information significantly change recognition measurement disclosure unrecognized tax benefit liability involve income tax specialist audit professional industry experience assist perform auditing procedure deloitte touche llp morristown new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item information fourth quarter director officer company adopt terminate active rule trading arrangement nonrule trading arrangement term define item regulation item disclosure foreign jurisdiction prevent inspection applicable report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp morristown new jersey february iii item director executive officer corporate governance reference proxy statement section director nominee respect information relate director incorporate reference hereof response information require item information require item respect executive officer include reliance general instruction instruction item regulation incorporate reference hereof response information require item reference proxy statement section govern govern code conduct respect code ethic incorporate reference hereof response information require item reference proxy statement section select elect director succession planning identification board candidate shareholder nomination director respect procedure shareholder recommend nominee board director incorporate reference hereof response information require item reference proxy statement section organize committees board respect audit committee incorporate reference hereof response information require item item executive compensation reference proxy statement section executive compensation incorporate reference hereof response information require item information executive compensation pay versus performance deem incorporate reference item security ownership certain beneficial owner management relate stockholder matter reference proxy statement vote security principal holder common stock ownership director executive officer respect security ownership certain beneficial owner management incorporate reference hereof response information require item reference proxy statement section item vote equity compensation plan information respect security authorize issuance equity compensation plan incorporate reference hereof response information require item item certain relationship relate transaction director independence reference proxy statement section govern govern relate party transaction respect certain relationship relate transaction incorporate reference hereof response information require item reference proxy statement section select elect director independence respect director independence incorporate reference hereof response information require item item principal accountant fee service reference proxy statement section item vote audit nonaudit fee item vote preapproval policy service provide independent register public accounting firm respect aggregate fee bill service provide principal accountant deloitte touche llp pcaob incorporate reference hereof response information require item item